▼ EPIDEMIOLOGY
Worldwide, oral carcinoma is one of the most prevalent cancers and is one of the 10 most common causes of death. Of the more than one million new cancers diagnosed annually in the United States, cancers of the oral cavity and oropharynx account for approximately 3%. 1 If oral cancers and cancers of the nasopharynx, pharynx, larynx, sinus, and salivary glands are combined, these sites represent more than 5% of total body cancers. In males, oral cancer represents 4% of total body cancers; in females, 2% of all cancers are oral. Oral cancer accounts for 2% of cancer deaths in males and 1% of cancer deaths in females. 1 The statistics are similar throughout North America but vary throughout the world; in French men, the incidence is up to 17.9 cases per 100,000 population, and high rates are reported in India and other Asian countries. Higher rates in these countries also are reported in females, with the highest rate in Singapore (5.8 cases per 100,000 population). 1 The majority of oral cancers are squamous cell cancers. Other malignant diseases that can occur in the head and neck include tumors of the salivary glands, thyroid gland, lymph nodes, bone, and soft tissue. However, these cancers are much less common, and this chapter thus focuses on squamous cell cancer.
Oral cancer is a disease of increasing age: approximately 95% of cases occur in people older than 40 years, with an average age at diagnosis of approximately 60 years. 2, 3 The agerelated incidence suggests that time-dependent factors result in the initiation and promotion of genetic events that result in malignant change. The majority of oral cancers involve the tongue, oropharynx, and floor of the mouth. [1] [2] [3] The lips, gingiva, dorsal tongue, and palate are less common sites. Primary squamous cell carcinoma of bone is rare; however, a tumor may develop from epithelial rests and from the epithelium of odontogenic lesions, including cysts and ameloblastoma. Individuals who have had a previous cancer are at high risk of developing a second oropharyngeal cancer. [4] [5] [6] [7] [8] African Americans in the United States have a higher risk of developing oropharyngeal cancer than do Caucasians. 2, 9, 10 The increased risk appears to be due to environmental factors; possible genetic factors have not been determined.
▼ ETIOLOGY AND RISK FACTORS
Evidence of the etiologic factors of squamous cell carcinoma is based on studies of at-risk groups, differences in incidence of disease, laboratory studies of malignant tissues, and animal studies. The incidence of oral cancer is clearly age related, which may reflect declining immune surveillance with age, time for the accumulation of genetic changes, and duration of exposure to initiators and promoters (these include chemical and physical irritants, viruses, hormonal effects, cellular aging, and decreased immunologic surveillance). Evidence from long-term follow-up of immunosuppressed patients after organ and bone marrow transplantation shows that immunosuppression increases the risk of the development of squamous cell carcinoma.
Tobacco and alcohol are acknowledged risk factors for oral and oropharyngeal cancer. 2, 3, [11] [12] [13] Tobacco contains potent carcinogens, including nitrosamines (nicotine), polycyclic aromatic hydrocarbons, nitrosodicthanolamine, nitrosoproline, and polonium. Nicotine is a powerful and addicting drug. Tobacco smoke contains carbon monoxide, thiocyanate, hydrogen cyanide, nicotine, and metabolites of these constituents. Epidemiologic studies have shown that of people with oral cancer, more than half smoke. 12, 14 One study demonstrated that 80% of patients with cancer were smokers. 4 In addition to the risk of primary cancers, the risk of subsequent primary oral cancers has been related to the continuing of smoking after treatment. [4] [5] [6] [7] [8] [15] [16] [17] Of patients who were observed for 1 year, 18% developed a second primary oral cancer, and those who continued to smoke had a 30% risk of second cancers. 4 The effect of smoking on cancer risk diminishes 5 to 10 years after quitting. Smoking has declined in North America, particularly in adults; approximately 30% of adults smoke. Unfortunately, this trend is not seen worldwide and is not shown in teenagers and young adults. The incidence of oral squamous cell cancer varies worldwide and may be explained partly by differences in the use of tobacco products. In parts of Asia where the use of tobacco, betal nuts, or lime to form a quid is widespread (e.g., India), the incidence of oral cancer is high. 2 Most studies have focused on cigarette use; however, other forms of tobacco use have been associated with oral cancers. The use of smokeless tobacco products (chewing tobacco and snuff) is of increasing concern due to the increase in their use and to their use at a young age. [18] [19] [20] [21] [22] [23] Benign hyperkeratosis and epithelial dysplasia have been documented after shortterm use, and it is likely that chronic use will be associated with an increasing incidence of malignant lesions. 2, 12, 24 All forms of alcohol, including "hard" liquor, wine, and beer, have been implicated in the etiology of oral cancer. In some studies, beer and wine may be associated with greater risk than is hard liquor. 12, 13 The combined effects of tobacco and alcohol result in a synergistic effect on the development of oral cancer. [11] [12] [13] [14] 16, [25] [26] [27] [28] The mechanism(s) by which alcohol and tobacco act synergistically may include dehydrating effects of alcohol on the mucosa, increasing mucosal permeability, and the effects of carcinogens contained in alcohol or tobacco. Secondary liver dysfunction and nutritional status also may play a role.
Factors for which no evidence of a role in oral cancer has been documented include denture use, denture irritation, irregular teeth or restorations, and chronic cheek-biting habits. 2, 3, 29, 30 However, it is possible that chronic trauma, in addition to other carcinogens, may promote the transformation of epithelial cells, as demonstrated in animal studies in which chronic trauma in addition to carcinogen application promotes tumor development. 31 In lip cancer, sun exposure, fair skin and a tendency to burn, pipe smoking, and alcohol are identified risk factors. 13 The decreasing incidence of lip cancer may reflect greater public awareness of the potential damaging effects of the sun. 2 High alcohol content in mouthwashes has been impli-cated in oral cancer. However, it has been suggested that smokers may use mouthwash more frequently; thus, the correlation between regular use of high-alcohol mouthwash and oral cancer may be confounded by alcohol and tobacco use. 13 In contrast with the well-documented risk associated with the use of alcohol and tobacco products, the role of other environmental agents (such as pollution)requires future study.
Pathogenesis
Oral squamous cell cancer (SCC) is the result of a multistage process from normal to dysplastic lesions and ultimately to SCC. A premalignant or precancerous lesion is defined by the World Health Organization as a morphologically altered tissue in which cancer is more likely to occur and includes oral leukoplakia, oral erythroplakia, and possibly oral lichen planus. Leukoplakia is a white patch of oral mucosa that cannot be characterized clinically or pathologically as any other diagnosed disease. Lesions should be defined by their probable cause, such as traumatic or tobacco-associated leukoplakia.
Dysplastic lesions have been categorized as mild, moderate, or severe, based on histomorphologic criteria. Mild dysplasia has dysplastic cells that are limited to the basal layer of the epithelium; moderate dysplasia and severe dysplasia involve increasing changes in cellular morphology and increasing thickness of the epithelium. Carcinoma in situ is a lesion in which abnormal cells involve the entire epithelium without invasion through the basement membrane, and carcinoma is diagnosed when there is disruption of the basement membrane and invasion into connective tissue.
The presence and severity of dysplasia is thought to have an impact on the malignant risk of premalignant lesions. Silverman and colleagues 32 found a mean of 7.2 years from diagnosis of leukoplakia to SCC although more than one-third of dysplastic lesions will progress to SCC whereas progression was seen in 15% of nondysplastic lesions. The current "gold standard" for predicting the malignant potential of premalignant lesions is the presence and degree of dysplasia. The risk of progression of leukoplakia varies from 0.13 to 24%, depending on the patients and the follow-up period. [32] [33] [34] The majority of leukoplakias (epithelial hyperplasia, mild dysplasia) do not progress to malignancy. Candida colonization has been associated with an increased risk of progression. 35 
Molecular Changes in Oral Cancer and Premalignancy
Carcinogenesis is a genetic process that leads to a change in morphology and in cellular behavior. The assessment of changes at the molecular level may become the primary means of diagnosis and may guide management since these changes mediate morphologic changes that occur after genetic changes, and knowledge of current morphologic changes is based on the subjective assessment of clinical and histopathologic changes. Major genes involved in head and neck squamous cell carcinoma (HNSCC) include proto-oncogenes and tumor suppressor genes (TSGs). Other factors that play a role in the progression of disease may include allelic loss at other chromosome regions, mutations to proto-oncogenes and TSGs, or epigenetic changes such as deoxyribonucleic acid (DNA) methylation or histone deacetylation. Cytokine growth factors, angiogenesis, cell adhesion molecules, immune function, and homeostatic regulation of surrounding normal cells could also play a role.
While proto-oncogenes increase cell growth and differentiation and are likely involved in carcinogenesis, few have been reported in HNSCC. Proto-oncogenes may function in coding for growth factors, growth factor receptors, protein kinases, signal transducers, nuclear phosphoproteins, and transcription factors. Proto-oncogenes associated with HNSCC include ras (rat sarcoma), cyclin-D1, myc, erb-b (erythroblastosis), bcl-1, bcl-2 (B-cell lymphoma), int-2, CK8, and CK19. 36 TSGs negatively regulate cell growth and differentiation. Functional loss of TSGs is common in carcinogenesis. 37 Both copies of a TSG must be inactivated or lost (loss of heterozygosity [LOH] ) for loss of function (the "two-hit" hypothesis). TSGs involved in HNSCC are p53, Rb (retinoblastoma), and p16INK4A. Other candidates include FHIT (fragile histidine triad), APC (adenomatous polyposis coli), DOC1 VHL (gene for von Hippel-Lindau syndrome), and TGF-βR-II (gene for transforming growth factor type II receptor). [38] [39] [40] [41] Chromosomes are numbered (1 to 23), and the arms of each chromosome are divided by the centromere into a short arm (designated P) and a long arm (designated Q). These TSGs have been associated with sites of chromosome abnormalities where LOH has been reported to commonly involve chromosome arms 3p, 4q, 8p, 9p, 11q, 13q, and 17p.
Loss on 3p and 9p are early and common events in oral carcinogenesis. Chromosome arm 3p may code for FHIT and is involved in epithelial cancers. Diadenosine tetraphosphate may accumulate in the absence of FHIT, which may lead to DNA synthesis and cell replication. TSGs at another site of 3p may include the VHL gene, which encodes membrane proteins that function in signal transduction and cell adhesion. LOH on 9p is seen in 72% of lesions and may represent the site for p16, which encodes a cell cycle protein that inhibits cyclin-dependent kinases and that arrests the cell cycle at the G 1 -S phase, and loss may lead to cell proliferation.
Later changes are seen on chromosomes 13 and 17 and are highly associated with progression to malignancy. LOH on 13q is identified in more than 50% of HNSCC. 36, 42 The putative TSGs are near the interferon locus and are close to the Rb locus. LOH on 13q has been associated with lymph node metastasis in HNSCC. LOH on 17p (the region of the p53 gene) is found in 50% of cases of HNSCC. The p53 protein functions in transcription activation, DNA repair, apoptosis, senescence, and G 1 and G 2 cell cycle inhibition.
Other genetic changes have been identified on chromosomes 4, 8, and 11. [43] [44] [45] [46] [47] Loss on chromosome 4 occurs in up to 80% of HNSCC cases; the putative TSG may be the epidermal growth factor (EGF) gene. Loss on 8p occurs in up to 67% of HNSCCs and is associated with a higher stage and a poor prognosis; the related TSG is unknown. Loss on chromosome 11 is present in up to 61% of HNSCCs; the common site lost may code the cyclin D1 gene. There is increasing evidence of the prognostic value of LOH in HNSCC. 42, 48 LOH on 13q correlates with lymph node metastases and recurrence in HNSCC.
Molecular staging may provide more precise predictions of the malignant potential than conventional clinicopathologic features do as it represents the fundamental biologic characteristics of each tumor. The current model of carcinogenesis is a multistage process, with loss occurring on chromosome arms 3p and 9p early in the lesion's progress from benign to dysplastic, with additional losses later in the disease, often involving 8p, 13q, and 17p. Putative TSGs at these sites of loss are p16 loss at 9p and p53 gene loss at 17p (Figure 8-1 ). Molecular markers are likely to become important clinical markers in diagnosis and staging and in treatment planning.
Earlier studies focused on LOH in SCC; currently, there is increasing study of LOH in premalignant lesions. 36, 39, 44, 45, 49, 50 LOH may predict the malignant risk of low-grade dysplastic oral epithelial lesions. 51, 52 This is of importance as the majority of oral premalignant lesions (hyperplasia, mild and moderate dysplasia) do not progress to cancer. Lesions that progress to SCC appear to differ genetically from nonprogressing lesions although they may not differ on the basis of histomorphologic findings. Progressing early lesions (low-grade dysplastic lesions and hyperplasia without dysplasia) are genetically different from morphologically similar nonprogressing lesions and molecular analysis may therefore become necessary in diagnosis. LOH at 3p and/or 9p occurs early in the majority of hyperplasias and mild dysplasias, and LOH on 17p occurs later. LOH on 8p occurs in 27% of dysplastic lesions and in 67% of invasive oral and laryngeal SCCs. LOH on 3p and/or 9p is seen in virtually all progressing cases and also in some nonprogressing cases. LOH on 3p and/or 9p (but no other chromosome arms) has a 3.8 times relative risk for developing SCC, and if additional sites of LOH are present (4q, 8p, 11q, 13q, or 17p), a 33-fold increase in risk of progression to cancer is seen. Accumulation of allelic loss is seen in progressing lesions, and the majority of progressing dysplasias have LOH on more than one arm (91%, vs 31% of nonprogressing dysplasias); 57% have loss on more than two arms (vs 20% of dysplasias without progression). LOH at 3p and/or 9p may be a prerequisite for the progression of oral premalignant lesions. LOH on 4q, 8p, 11q, 13q, and 17p is common in severe dysplasia/carcinoma-in-situ (CIS) or SCC.
The importance of the study of TSG loss (LOH) is that both the tumor and the precancer have an increasing aggressive nature with increasing molecular changes. Molecular changes predate the current morphologic criteria for diagnosis and for determining margins. It may be possible to assess risk based on TSG loss, to predict risk for metastases and recurrences of lesions, and to guide current therapy by indicating treatment volumes (margins). In the future, treatment may be directed at the function of proto-oncogenes or TSGs rather than to current therapies with their associated toxicities. TSG changes may provide tools for prognosis and may serve as intermediate markers in assessing treatment and prevention outcomes.
▼ PROGNOSIS
The American Joint Committee on Cancer (AJCC) has developed the tumor, node, metastasis (TNM) system of cancer classification. 53 The AJCC classification is principally a clinical description of the disease but also includes imaging in the classification. The TNM staging of tumors of the oral cavity is shown in Table 8 -1. In the oral cavity, T is determined by the size of the primary tumor, N indicates the presence of tumor in lymph nodes, and M indicates distant metastasis. The staging system has combined the T, N, and M to classify lesions as stages 1 to 4. However, when these factors are combined for staging, tumors with different behaviors may be staged similarly; therefore, classification by TNM description is now more common than combining these factors into the four staging groups. For example, there may be differences in biology and response to treatment between a stage 3 tumor that is classified as T1 N1 M0 and a stage 3 tumor that is classed as T3 N0 M0.
Local or regional spread of oral SSC is common and affects the choice of therapy and prognosis. Metastases to cervical lymph nodes are common, but distant metastases below the clavicle are rare. Oral cancer occurring in the posterior aspect of the oral cavity and oropharynx and inferior in the mouth tends to be associated with a poorer prognosis, which may be explained by diagnosis occurring with advanced disease and by a higher incidence of spread to lymph nodes at the time of diagnosis. Ipsilateral lymph node metastases are frequent; however, spread to contralateral nodes also occurs and is more common with midline and posterior lesions.
The most important factor in survival is the stage of disease at diagnosis. Unfortunately, the majority of oral cancers are diagnosed after becoming symptomatic. 3 Since 1960, some progress has been seen with an increase in 5-year survival rates from 45 to 53%. 1 African Americans have had a poorer 5-year survival rate and continue to have a survival rate of less than one-third as compared to caucasians, who have a 5-year survival rate of 53%. 1,2,9,10 These survival rates may be conditioned by physical and social environment; lack of knowledge; risk-promoting lifestyle, attitude, and behavior; and limited access to health care. At least half of the difference in survival in the poor has been attributed to late diagnosis. 9, 10 The incidence of spread is influenced by tumor size. Lesions classed as T1 may show regional spread in 10 to 20% of cases, T2 lesions in 25 to 30% of cases, and T3 to T4 tumors in 50 to 75%. [54] [55] [56] A 3-year follow-up with no evidence of disease occurs with approximately 75 to 85% of T1 lesions, 50 to 60% of T2 lesions, and 20 to 30% of T3 to T4 lesions. 57 For patients without lymph node involvement, the overall 3-year no-evidence-of-disease rate is approximately 50 to 60%; however, with lymph node involvement, the rate of cure is approximately 33 to 50%. 58 Review of the report of the National Cancer Data Base 59 indicated that patients with localized tumors of the oral cavity and pharynx have an overall survival rate of 70%. The database showed an 81% survival rate for those who were treated with surgery alone, a 70% survival rate for those treated with surgery and radiation combined, and a 55% survival rate for those treated with radiation alone. For patients with regional disease, overall survival was 46%; survival rates were 60% for those treated with surgery alone, 58% for those treated with combined surgery and radiation, and 39% for those treated with radiation alone. For patients with distant metastases, overall survival was 33%.
The National Cancer Institute's Surveillance, Epidemiology and End Results program shows relative survival rates of 51% over a 5-year period and a 10-year survival rate of 41%. 60 Progress in the control of oral and pharyngeal cancer has been seen in years of life lost due to cancer: 23.1 years in 1970 and 19.9 years in 1985. 61 There is rarely a second chance for a cure; therefore, the initial approach to therapy is critical. Death from head and neck cancer may be due to erosion of major vessels, erosion of the cranial base, cachexia, and secondary infection of the respiratory tract. A thorough understanding of each treatment modality, its efficacy, and its side effects is needed, which has led to the need for a team approach that may include surgeons, radiation oncologists, medical oncologists, dentists, and adjunctive health care workers.
▼ PRECANCEROUS LESIONS

Leukoplakia and Erythroplakia
CLASSIFICATION AND DIAGNOSIS
Histomorphologic classifications of oral leukoplakia have been proposed, to assist in predicting which oral lesions are at increased risk of progression to cancer. The more recent proposals are similar to each other (Table 8-2) . 62, 63 The classifications include histologic findings and the clinical description, site, and size of the lesion. The site of the lesion has been associated with increased risk and is included in the more complex classification, as shown.
Early detection of dysplastic and malignant lesions is a continuing goal. Thorough head and neck and intraoral examination is a prerequisite. Aids to oral examination include vital tissue staining using toluidine blue and (more recently) computer-assisted cytology of oral brush biopsy specimens. 64 Toluidine blue can be applied directly to suspicious lesions or used as an oral rinse. A study of the application of toluidine blue to a consecutive series of patients who had prior head and neck cancer and in whom all lesions were examined by biopsy revealed 100% of the carcinomas in situ and SCCs (no falsenegatives; sensitivity was 100%) whereas clinical findings would not have led to biopsy being performed on 28% of these malignant lesions (p = .02). 65 Toluidine blue has documented clinical use in choosing biopsy sites, may guide surgical treatment of malignant lesions, and facilitates the decision to perform a biopsy. The assessment of dye uptake depends on clinical judgment and experience (Figures 8-2 and 8-3 ). Positive retention of toluidine blue (particularly in areas of leukoplakia, erythroplakia, and uptake in a peripheral pattern of an ulcer) may indicate the need for biopsy. False-positive dye retention may occur in inflammatory and ulcerative lesions, but false-negative retention is uncommon. 65 A return appointment in 14 days, providing time for inflammatory lesions to improve, may lead to a decrease in false-positive results. However, the definitive test is biopsy, and any suspicious lesion should not remain undiagnosed. Toluidine blue provides guidance for the selection for the biopsy site and indicates sites that are at risk for malignancy in wide areas of leukoplakia. Toluidine blue can provide additional aid in determining the margins of a lesion for treatment purposes. In postradiotherapy follow-up, the retention of toluidine blue may act as a guide indicating the distinction between chronic nonhealing ulcers and persistent or recurrent disease.
Computer-assisted analysis of oral brush cytology is completed on Pap-stained exfoliated cells, scanned by computer for abnormal cell morphology and keratinization, and a final diagnosis is made by an examining pathologist on the basis of standard histomorphologic criteria. This approach was evaluated in 945 patients, of whom only approximately one-third underwent biopsy, and true positives were reported in 100% of the lesions that were positive by brush cytology (sensitivity, 100%; no false-negatives); unfortunately, not all patients underwent biopsy, and false-negative results are not evaluable Adapted from Pindborg JJ et al; 62 Schepman KP et al. 63 FOM = floor of the mouth. for the whole group. Of importance, 4.5% of clinically benign lesions that were positive on brush cytology were subsequently evaluated by biopsy and diagnosed as dysplasia or SCC. Brush cytology may be useful, and it can be used in conjunction with vital staining. 64 Future developments may include studies of exfoliated cells by using molecular markers of dysplasia or carcinoma to improve the diagnostic and prognostic value. A recent study showed that exfoliative epithelial cells have the same genetic changes associated with dysplasia and cancer as did paired biopsy specimens. 66 
CLINICAL FEATURES
Leukoplakia is a white lesion that involves the oral mucosa, cannot be removed by rubbing, and cannot be classified as any other lesion following histopathologic examination ( Figures 8-4 and 8-5). Leukoplakia can affect any area of the oral mucosa and most commonly represents benign keratosis. Leukoplakia has been associated with trauma and tobacco use. A dose-response relationship exists between leukoplakia and the frequency and duration of tobacco use. At the time of identification of leukoplakia, biopsy reveals dysplasia in 12 to 25% of patients and reveals carcinoma in 3 to 10%. 32, [67] [68] [69] [70] [71] [72] Dysplasia is present more frequently in leukoplakia that involves the tongue, lips, and floor of the mouth and less frequently in leukoplakia that involves the palate and retromolar regions. The presence of dysplasia within a leukoplakia lesion implies an increased risk of malignant transformation. In studies with a mean follow-up of more than 7 years, the incidence of malignant transformation of leukoplakia has varied from less than 1% to 17.5%, with the most common range being 2 to 6%. 32, 73, 74 Leukoplakia associated with tobacco use is frequently reversible with the discontinuance of tobacco use. Spontaneous regression of leukoplakia also has been seen in these follow-up studies.
Proliferative verrucous leukoplakia (PVL) is a unique verrucous form of oral leukoplakia that is associated with a high risk of progression to squamous cell carcinoma. The lesion is more common in males. In one study, the mean age was more than 62 years, and over 70% of the lesions progressed to carcinoma. 75 PVL has been associated with human papillomavirus (HPV) type 16. 76 Aggressive management and close follow-up is needed.
Leukoplakia has been regarded as the most common oral presentation of cancer; however, it has been shown that erythroplakia and irregular erythroleukoplakia are at a greater risk of being dysplastic or malignant than are white lesions. 2, 3, 72 Erythroplakic lesions may be malignant or dysplastic in up to 80% of tissue biopsy specimens 3, 72 (Figure 8-6 ). In a study of asymptomatic oral cancers, 60% were mixed leukoerythroplakic, one third were erythroplastic, and 4.9% were white lesions. 77 The risk of malignant transformation of erythroplakia has been shown to have four to seven times the risk of change in leukoplakia. 32, 70, 72, 73, 78, 79 FIGURE 8-3 The same case shown in Figure 8 -2 following application of toluidine blue. Dye retention was consistent with dysplasia or carcinoma and indicated the best site for biopsy. The biopsy specimen was reported as squamous cell carcinoma. cell carcinoma, further study is required because some biotypes may transform carcinogenic nitrosamines from precursors. 72 
Lichen Planus
Lichen planus is an immunologically mediated mucocutaneous disease primarily seen in adults, more commonly in women. Chronic lichen planus has been shown to present a low but measurable risk of cancer, 2, 72 and oral cancer has been identified as arising from areas of erythematous atrophic lichen planus. 72, [84] [85] [86] [87] Malignant transformation of lichen planus has been reported in 0.4 to 2.5% of cases in long-term studies, which represents a 50-fold or greater increase in risk. Other reports have questioned the prevalence of malignant transformation of lichen planus because of the lack of detail and uniformity of diagnosis presented in the literature and because the epidemiology suggests that the majority of cases of SCC would be related to the transformation of lichen planus, if above estimates are correct. 88 
Syphilis and Submucous Fibrosis
A relationship between syphilis and oral cancer has been discussed, but the evidence is equivocal. 2 The oral lesions of syphilis may need to be differentiated from oral malignant lesions.
Submucous fibrosis is a disease of the oral mucosa, characterized by epithelial atrophy and fibrosis of the submucosa. Submucous fibrosis is most common among East Indians. While the etiology is unknown, consumption of spices and irritants has been suspected to be the cause. Squamous cell carcinoma has been described in up to one-third of patients with submucous fibrosis.
Oral Hairy Leukoplakia
Oral hairy leukoplakia presents as a vertical folded white patch most frequently seen on the lateral borders of the tongue (Figure 8-9 ). It may occur in patients with chronic immunosuppression and is associated with the presence of Epstein-Barr virus. While most common in people with human immunodeficiency virus (HIV) infection, it has been reported in
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The use of smokeless tobacco has increased and has been associated with oral leukoplakia 24, 72, 80, 81 (Figure 8-7) . The presence of leukoplakia in adolescent users of smokeless tobacco is related to years of use, frequency of use, and the amount used. 80 Malignant transformation of leukoplakia may occur in 0.5 to 6.2% of individuals 80, 81 and is expected to increase with years of use (Figure 8-8) . A 50-fold increased risk of oral carcinoma has been estimated for female snuff dippers. 24 A cocarcinogenic effect of smokeless tobacco and HPV 56 and extracts from smokeless tobacco and herpes simplex virus infection has been shown in vitro. 82, 83 Leukoplakia is less common in people who do not use tobacco products. Paradoxically, leukoplakia in individuals who do not use tobacco has a greater risk of malignant transformation, which suggests other etiologic factors in these cases.
Candida is often associated with leukoplakia, and a higher prevalence has been seen in erythroplakia. 2, 72 The presence of Candida may represent secondary colonization. While there is little evidence to implicate Candida in the causing of squamous The leukoplakia demonstrated dysplasia, and in the right maxillary gingiva, invasive squamous cell carcinoma was diagnosed. In the area of carcinoma, increased thickening, ulceration, and palpable thickness were noted.
patients after organ and bone marrow transplantation. When Candida is associated with the lesion, it colonizes secondarily. Evidence of premalignant potential, abnormal keratin, and dysplasia has not been seen in hairy leukoplakia.
Management of Leukoplakia
In managing leukoplakia, risk factors must be eliminated if at all possible. If leukoplakia is not reversed, treatment may be indicated. Therapy is needed when dysplasia is seen on biopsy specimens. Treatment may include excision and topical therapies. Laser excision/ablation using carbon dioxide laser and neodymium:yttrium-aluminum-garnet (Nd:YAG) laser has been reported as effective although recurrence of lesions is not uncommon. 89 The potential advantage of laser therapy is improved healing of the treated area; however, a potential disadvantage is the inability to carefully assess histologic margins. Topical application of vitamin A acid may achieve remission in cases of mild dysplasia; 2,90-92 however, lesions often recur when therapy is discontinued. Systemic retinoids (analogues of vitamin A) have antiproliferative and differentiating effects on human squamous epithelial cells. In addition, retinoids may play a role in reducing the risk of recurrence or second primary lesions although recurrence of the lesion is common if the retinoid is discontinued. 93, 94 Bleomycin has been applied in a topical solution of dimethyl sulfoxide and has shown reduction and elimination of oral lesions in short-and long-term follow-ups. 95, 96 Close follow-up is needed for persistent leukoplakia as some of these lesions will progress to SCC. If changes in behavior or appearance occur, a repeat biopsy is indicated.
▼ VIRUSES IN ORAL CANCER
The potential role of viruses in oral cancer is under continuing study. The interaction of viruses with other carcinogens and oncogenes may be an important mechanism of disease.
Herpes simplex virus (HSV) has been shown to produce a number of mutations in cells. 97 A cocarcinogenic effect between HSV and chewing tobacco has been demonstrated in animal studies. 82, 83, 98 Smokers demonstrate higher antibody titers to HSV, suggesting reactivation. 99, 100 Neutralizing antibodies to HSV are present in the serum of patients with oral cancer at higher titers in those who have advanced cancer, and antibody response to HSV antigen is greater in patients than in controls. 99, 100 However, HSV has not been detected in human squamous cell carcinoma. 97, 101 If HSV is etiologic, it is likely that the virus has an effect which leaves no evidence of its presence after its oncogenic effect (a "hitand-run" effect). 97, 102 HPVs are being studied in oral cancer. In laboratory studies, HPVs can transform cells. The association of HPV with anogenital and cervical dysplasia, carcinoma in situ, and invasive carcinoma has been well established. 72, 97, 103, 104 The sensitivity of methods and the sequences of DNA selected for study may explain the variability of findings in the study of HPV in oral squamous cell carcinoma. In some studies, approximately one-half of oral squamous cell carcinomas contain HPV types 16 or 18 (HPV-16 or -18). 72, [105] [106] [107] [108] When studied by using polymerase chain reaction, 90% of oral carcinomas were found to contain HPV-16 or HPV-18. 108 However, additional study is needed due to inconsistent findings in some studies with respect to the presence of HPV or the presence of fragments of the HPV genome. 72, 104, [108] [109] [110] [111] [112] ▼ TUMOR BIOLOGY Studies of the repair mechanisms of cellular damage may play a role in the understanding of malignant disease and in its therapy in the future. 72, 113 Oncogene amplification has been seen in oral carcinoma. Genetic risk and cocarcinogenesis are continuing to be investigated (see above). The role of cytokines, including epidermal and transforming growth factors, may be relevant in oral squamous cell carcinoma. 72, 113, 114 Changes in cell surface receptors and major histocompatibility class I and class II antigens have been seen and may indicate that immune surveillance and immune function may be affected in patients with oral cancer. 114 The changes noted in human leukocyte antigen expression may be useful in the prognosis of tumor behavior. Other cell surface changes include a loss of cytoplasmic membrane binding of lectins, which has been shown to correlate to the degree of cellular atypia. Cell surface markers are altered in neoplastic dedifferentiation; examples are the loss of ABO blood group antigens, beta 2 -microglobulin, and involucrin and a loss of reaction to pemphigus antisera. Alterations in cell-bound immunoglobulins and circulating immunocomplexes are detectable, but the importance of these changes in pathogenesis is unclear. Carcinoembryonic antigens are elevated in patients with oral cancer. Intracellular enzymes also are altered or lost, commensurate with the degree of cellular dysplasia.
The development of malignant disease in immunosuppressed patients indicates the importance of an intact immune response. Mononuclear cell infiltration correlates with prognosis, and more aggressive disease is associated with limited inflammatory response. Total numbers of T cells are decreased in patients with head and neck cancer. The mixed lymphocyte reaction is reduced in some patients, and a diminished migration of macrophages has been demonstrated. Cluster designation 8 (CD8) lymphocytes (T suppressor cells) predominate in the infiltrate, suggesting an evolving immunosuppression with progression to invasive carcinoma. Langerhans' cells (intraepithelial macrophages) are slightly increased in neoplastic epithelium; however, in animal models of chemical-induced carcinogenesis, Langerhans' cells are decreased. Further understanding of immune function and the response to SCC may lead to the development of new therapies that modulate the immune response. 113 Squamous cell carcinoma primarily spreads by direct local extension and by regional extension through the lymphatics. Regional spread in the oral mucosa may occur by direct extension and sometimes by submucosal spread, which may result in wide areas of involvement. Bone involvement occurs when the periosteal barrier is violated. Production of type I collagenase and other proteinases, prostaglandin E 2 , and interleukin-1 may affect the extracellular matrix, and motility of epithelial cells may allow invasion. 72, 91, 114 Changes in the basement membrane, such as the breakdown of laminin and collagen, occur with invasion. Understanding the biology of invasion by malignant cells may lead to additional approaches to diagnosis and management.
▼ NUTRITION: RISK AND PROPHYLAXIS
Vitamin A may play a role in oral cancer. 2, [115] [116] [117] [118] This hypothesis is based on population studies in which deficiency was associated with risk of squamous cell carcinoma, on population studies of vitamin A and carotenoid supplementation, and on studies of reduction in carcinogenesis in animal models. Vitamin A may cause regression of premalignant leukoplakia, and the prophylactic use of supplementation in patients at high risk of recurrent or new secondary squamous cell carcinoma is being studied. A review (based on a study conducted by the National Toxicology Program) of the benefits and risks of fluoride use demonstrated equivocal evidence of carcinogenicity of fluoride in male rats. 119 The evidence was based on the finding of a few cases of osteosarcoma in male rats, but in female rats and in male and female mice, no malignant disease was seen. 119 Other animal studies have not confirmed these results. There is no epidemiologic evidence of an association between fluoride and osteosarcoma or other malignant disease in humans. 72, 119, 120 
▼ PRESENTING SIGNS AND SYMPTOMS
Oral cancer is initially asymptomatic, and unfortunately, patients are most often identified only after the development of symptoms and after progression of disease. Discomfort is the most common symptom that leads a patient to seek care
and is present at the time of diagnosis in up to 85% of patients. 2, 121 Patients also may present with an awareness of a mass in the mouth or neck. Dysphagia, odynophagia, otalgia, limited movement, and oral bleeding occur less frequently. The oral cavity should be examined following a careful assessment of the cervical and submandibular lymph nodes. Examination of the oral cavity should not neglect any area, but the high-risk sites for oral carcinoma must be most carefully examined. The patient should be assessed for tissue changes that may include a red, white, or mixed red-and-white lesion; a change in the surface texture of the lesion, producing a smooth, granular, rough, or crusted lesion; or the presence of a mass or ulceration (Figures 8-10 to [8] [9] [10] [11] [12] [13] [14] . The lesion may be flat or elevated and ulcerated or nonulcerated, and it may be minimally palpable or indurated. Loss of function involving the tongue can affect speech, swallowing, and diet.
Lymphatic spread of oral carcinoma usually involves the submandibular and digastric nodes, the upper cervical nodes, and finally the remaining nodes along the cervical chain. The nodes most commonly involved are those that are on the same side as the primary tumor although the closer the tumor is to the midline and the more posterior it is in the oral cavity or oropharynx, the more common is the involvement of the bilateral and contralateral nodes. Lymph node involvement may not occur in an orderly fashion, and thorough examination is mandatory. Lymph nodes associated with cancer become enlarged and firm to hard in texture. The nodes are not tender unless they are associated with secondary infection or unless an inflammatory response is present, such as may occur after a biopsy. The fixation of nodes to adjacent tissue due to invasion of cells through the capsule is a late occurrence. The fixation of the primary tumor to adjacent tissue overlying bone suggests the involvement of periosteum and possible spread to bone. Spread of tumor is critical for prognosis and for selection of treatment. It is critical that the status of the lymph nodes be carefully assessed before a biopsy is performed. The understaging of nodes by cursory assessment or the overstaging of nodes following a biopsy, when an inflammatory component may be present, has dramatic effects on the selection of treatment. Therefore, accurate node examination is needed before biopsy, and the individual who is performing the procedure must be experienced in lymph node palpation.
▼ IMAGING
Imaging, including routine radiology, computed tomography (CT), nuclear scintiscanning, magnetic resonance imaging (MRI), and ultrasonography, can provide evidence of bone involvement and can indicate the extent of some softtissue lesions.
Bone involvement is important in staging, selecting therapy, and determining the prognosis. Determination of bone involvement is based on imaging and on clinical and histologic findings. Imaging to determine bone involvement may be done by routine radiology, CT, and bone scanning ( Figures  8-15 to 8-21 ). Nuclear scintiscanning may provide evidence of bone involvement by tumor and bony necrosis following radiation therapy. MRI is of limited value in determining bone involvement but may show distortion of bony trabeculae. Future developments may include monoclonal antibodies linked to a radiolabel to enhance the sensitivity and specificity of the imaging.
Soft-tissue involvement of the antrum and nasopharynx can be assessed with CT and MRI. Panoramic radiography of patients with antral carcinoma may document the lesion in a large number of such cases. MRI is rapidly replacing CT as the imaging technique of choice for the head and neck. 122 Each MRI image should include T1-weighted images, which demonstrate normal anatomy with detail and soft-tissue definition, and T2-weighted images, which demonstrate the tumor in comparison to adjacent muscle and other soft tissues. MRI will allow more accurate distinctions between tumor and benign inflammatory disease than CT allows and may be useful in assessing the sinus. Motion distortion can 
FIGURE 8-12
Shallow ulcer involving the soft palate. The margins were rolled and palpably thickened. The differential diagnosis may include traumatic ulcer, tumor of salivary gland, necrotizing sialometaplasia, and squamous cell carcinoma. Squamous cell carcinoma was demonstrated on biopsy.
FIGURE 8-13
Extensive firm mass filling the hard palate was diagnosed on biopsy as squamous cell carcinoma. The tumor mass had caused destruction of the alveolar bone and invaded the antrum.
FIGURE 8-14
Exophytic firm mass with an irregular erythroleukoplakic surface. Pathology revealed squamous cell carcinoma. The mass was not mobile, which suggested bone involvement.
limit its imaging, particularly in moving tissues, but the continuing development of MRI is resulting in less time being needed for imaging.
CT and MRI aid in determining the status of the cervical lymph nodes. There is evidence that imaging will enhance the findings of expert clinical examination when positive lymph nodes are being sought. 123 Small-part ultrasonography may be of value for imaging salivary gland masses and for the assessment of lymph nodes; however, differentiation between benign and malignant nodes may not be possible. The ultrasonographically guided needle biopsy technique may be useful in the assessment of head and neck masses, including lymph nodes.
In the assessment of metastases to the lung, conventional radiography will detect advanced involvement (> 1 cm); detection of smaller masses or lymph nodes is possible with CT.
▼ ACQUISITION OF A TISSUE SPECIMEN
In addition to the standard biopsy techniques of incision and excision, tissue also can be acquired for histopathology by using fine-needle aspiration (FNA). Open biopsy of enlarged lymph nodes is not recommended; in such cases, FNA biopsy should be considered. FNA also may aid the evaluation of suspicious masses in other areas of the head and neck, including masses that involve the salivary glands, tongue, and palate. Exfoliative cytology is of limited value in the assessment of cancer because squamous mucosa is difficult to sample to the basal epithelium (which is needed to assess dysplasia) and because only keratin may be acquired in keratinized mucosa. Thus, false-negative results may provide a false sense of comfort and may delay diagnosis. However, if the entire thickness of the epithelium (including basal cells) can be sampled (as has been suggested as possible by using a brush cytology technique), improved diagnostic value may be achieved. An additional means of improving diagnostic value may be the application of molecular markers to exfoliated cells since LOH at sites of putative TSGs in exfoliated cells has been shown to reflect those found on biopsy. 66 
▼ HISTOPATHOLOGY
Microscopic examination is required for diagnosis. Dysplasia or atypia describes a range of cellular abnormalities that includes changes in cell size and morphology, increased mitotic figures, hyperchromatism, and alteration in normal cellular orientation and maturation. The descriptions of mild, moderate, and severe dysplasia refer to epithelial abnormality of varying severity. When the abnormality does not involve the full thickness of the epithelium, the diagnosis is carcinoma in situ. When the basement membrane is violated and connective-tissue invasion occurs, carcinoma is diagnosed. Well-differentiated carcinoma may retain some anatomic features of epithelial cells and may retain the ability to produce keratin whereas poorly differentiated carcinoma loses the anatomic pattern and function of epithelium. Tumors may be associated with a mixed inflammatory infiltrate. Inflammatory and reactive lesions can be difficult to differentiate from dysplasia, and the experience of the pathologist becomes important with the need for clinical reassessment and repeat investigation.
Recognition of tumor invasion may be assisted by a study of type IV collagen (basement membrane collagen) by immunocytochemistry. 114 Invasion of lymphatics, blood vessels, and perineural spaces is of critical importance but is difficult to determine. 114 Currently, diagnosis is based on the interpretation of histomorphologic changes. However, these changes appear following molecular change, and it is possible that when molecular markers become automated, they will provide additional information and may ultimately become the gold standard in diagnosis.
▼ TREATMENT OF ORAL CANCER
The principle objective of treatment is to cure the patient of cancer. The choice of treatment depends on such factors as cell type and degree of differentiation; the site, size, and location of the primary lesion; lymph node status; the presence of bone involvement; the ability to achieve adequate surgical margins; the ability to preserve speech; the ability to preserve swallowing function; the physical and mental status of the patient; a thorough assessment of the potential complications of each therapy; the experience of the surgeon and radiotherapist; and the personal preferences and cooperation of the patient. If the lesion is not cured by the initial therapy, the options for treatment may be limited, and the likelihood of cure may be reduced.
Surgery or radiation are used with curative intent in the treatment of oral cancer. Chemotherapy is an adjunct to the principal therapeutic modalities of radiation and surgery. Either surgery or radiation may be used for many T1 and T2 lesions; however, combined surgery and radiation is usually needed for more advanced disease. For advanced disease, chemotherapy is used in combination with either or both of the primary treatment modalities.
Surgery
Surgery may be the primary treatment or may be part of combined treatment with radiation therapy. Surgery is indicated (1) for tumors involving bone, (2) when the side effects of surgery are expected to be less significant than those associated with radiation, (3) for tumors that lack sensitivity to radiation, and (4) for recurrent tumor in areas that have previously received a maximum dose of radiotherapy. Surgery also may be used in palliative cases to reduce the bulk of the tumor and to promote drainage from a blocked cavity (eg, antrum). Surgery may fail due to incomplete excision, inadequate margins of resection, tumor seeding in the wound, unrecognized lymphatic or hematogenous spread, neural invasion, or perineural spread. Adequate surgical margins are required but may not be attainable due to the size and location of the tumor. Surgery results in a necessary sacrifice of structure, which may have important esthetic and functional considerations. Future advances in treatment may include surgery combined with systemic chemotherapy and immunotherapy, and there also may be advances in reconstruction.
Surgical management of clinically positive cervical nodes is the treatment of choice. Surgery is needed when bone is involved, and radiotherapy alone cannot be considered adequate to produce a cure. In some cases with minimal bone involvement of the alveolar crest, a partial mandibulectomy may allow the continuity of the mandible to be maintained. However, in many cases, mandibulectomy and resection in continuity with the involved nodes are required.
Radical neck dissection may be conducted as part of an en bloc resection of tumor with lymph node metastases and can be combined with radiation therapy when the primary tumor is treated by radiotherapy. Neck dissection can be used in salvage treatment of cancer that has recurred in the neck. Tumors with node involvement should be treated aggressively due to the poorer prognosis that is seen with positive nodes.
Surgical excision of dysplastic and malignant lesions can be accomplished with laser therapy. Laser therapy for these lesions is well tolerated and usually decreases the period of hospitalization but has the disadvantage of limiting the assessment of the margins for histopathologic confirmation.
Advances in surgical management have taken the form of new surgical approaches and new approaches to reconstruction, such as vascularized flaps and free microvascular reconstruction. 123 Reconstruction with the use of osseointegrated implants offers the ability to provide stable prostheses and enhanced functional results. The ability to place implants in irradiated bone has increased options for rehabilitation.
Radiation Therapy
Radiation therapy may be administered with intent to cure, as part of a combined radiation-surgery and/or chemotherapy management, or for palliation. Radical radiotherapy is intended to cure. The total dose is high, the course of radiation is prolonged, and early and late radiation effects are common. In palliative care, radiation may provide symptomatic relief from pain, bleeding, ulceration, and oropharyngeal obstruction. Hyperfractionation of radiation (usually twicedaily dosing) is being used more extensively as chronic complications appear to be reduced although acute complications are more severe.
Radiation kills cells by interaction with water molecules in the cells, producing charged molecules that interact with biochemical processes in the cells. DNA is disrupted, and chromosomal damage occurs. The affected cells may die or remain incapable of division. Due to a greater potential for cell repair in normal tissue than in malignant cells and a greater susceptibility to radiation due to the higher growth fraction of cancer cells, a differential effect is achieved. To result in an enhanced therapeutic effect, radiation therapy is delivered in daily fractions for a planned number of days. The relatively hypoxic central tumor cells are less susceptible to radiotherapy, but they may become better oxygenated as peripheral cells are affected by radiation and are thus more susceptible to subsequent fractions of radiation. 124 The biologic effect of radiation depends on the dose per fraction, the number of fractions per day, the total treatment time, and the total dose of radiation. Methods for representing the factors of dose, fraction size, and time of radiation with a single calculation using the time-dose fraction (TDF) and the nominal standard dose (NSD) calculations have been described. [124] [125] [126] When comparing studies of radiation effect and when describing the results of studies of cancer patients treated with radiotherapy, reporting the total dose is inadequate because of the importance of fraction size and the time of therapy (which are not available for comparison). The use of the TDF or the NSD will facilitate the understanding of the biologic effect. The tolerance of the vascular and connective tissues to radiation influences both the success of tumor control and the development of treatment complications. The late complications of radiotherapy are due to effects on vascular, connective, and slowly proliferating parenchymal tissues. Late effects are related to the number of fractions, the fraction size, the total dose, the tissue type, and the volume of tissue irradiated. An increase in fraction size or a reduction in the number of fractions with the same total dose results in increased late complications, including tissue fibrosis and soft-tissue and bone necrosis. 127 It is well known that a relationship exists between the dose of radiation and the survival of a cell population. Cell survival is influenced by the repair of sublethal damage, oxygenation of the cells, total dose, fraction size, and the type of radiation used. Standard single-fraction irradiation protocols deliver 1.8 to 2 Gy to tissue, without significant complications.
SSCs are usually radiosensitive, and early lesions are highly curable. In general, the more differentiated the tumor, the less rapid will be the response to radiotherapy. Exophytic and well-oxygenated tumors are more radiosensitive whereas large invasive tumors with small growth fractions are less responsive. SSC that is limited to the mucosa is highly curable with radiotherapy; however, tumor spread to bone reduces the probability of cure with radiation alone. Small cervical metastases may be controlled with radiation therapy alone although advanced cervical node involvement is better managed with combined therapy.
Radiation therapy has the advantage of treating the disease in situ and avoiding the need for the removal of tissue, and it may be the treatment of choice for many T1 and T2 tumors. Radiation may be administered to a localized lesion by using implant techniques (brachytherapy) or to a region of the head and neck by using external-beam radiation. External-beam therapy can be provided in such a way as to protect adjacent uninvolved tissues, with enhanced effects by using smaller boost fields or by combining external-beam and interstitial techniques. Three-dimensional conformal radiation therapy also enhances the sparing of nonmalignant tissue. Primary tumors of the posterior third of the tongue, oropharynx, and tonsillar pillar are best treated by external-beam radiotherapy, and surgery is reserved for the treatment of tumors with node involvement. Larger radiation fields result in increased patient complications. Smaller fields may be used to boost the dose to the central portion of the tumor since control of peripheral well-oxygenated cells may be possible at a lower dose than that used for the central lesswell-oxygenated tumor mass.
RADIATION SOURCES
For treatment of superficial tumors, radiation with a low penetration may be used. Low-kilovolt radiation (50 to 300 kV) can be used in the treatment of skin and lip lesions. Electron beam therapy provides superficial radiation and has largely replaced low-kilovolt x-ray machines because electrons produce a rapid dose buildup and a sharp falloff of dose; thus, the depth of penetration can be relatively controlled. Electrons may be useful in providing radiation to skin lesions, parotid tumors, and cervical nodes. Deep-seated tumors may be treated with heavyparticle irradiation, such as neutron beam radiation.
Megavoltage radiation using cobalt 60 or the use of a linear accelerator of ≥ 4 MeV is reported to be skin and bone sparing. The linear accelerator provides variable penetration due to its ability to vary the energy of the photons.
TREATMENT PLANNING
The radiation treatment plan is determined by tumor site, tumor size, the total volume to be radiated, the number of treatment fractions, the total number of days of treatment, and the tolerance of the patient. Treatment planning in radiation therapy includes planning for the sparing of uninvolved tissues or organs. The dose to the eye or spinal cord, salivary glands, alveolar bone, and soft tissue can be limited through the selection of the radiation source, field set-up, and shielding and by moving the uninvolved tissue out of the field.
For repeated doses of radiation to be applied to the site of treatment, the patient and the area of treatment must be immobilized. The head can be immobilized by using various techniques and materials, including head holders; bandages; laser positioning, using head and neck "landmarks" or tattoos; and custom acrylic shells (mould room technique). These techniques may be combined with an oral device to position the mandible, allowing the maxilla or mandible to be moved into or out of the radiation field (Figures 8-22 to 8-24) . The oral device can incorporate a tongue depressor to position the tongue in or out of the treatment field. This device can be made by using an acrylic tube around which wax is placed. Impressions in warmed baseplate wax can be readily accomplished with bite pressure. The tube serves as a handle and can facilitate respiration. The device can be left as wax or can be processed in acrylic.
Treatment planning requires localization of the tumor and radiation planning. The margins of the tumor can be marked with radiopaque gold seeds or lead wire. If a shell is used, markings can be placed on the shell, or entrance and exit sites can be marked by a tattoo on the skin (Figures 8-25 to 8-27 ). The contours of the radiation field can be estimated by computer modeling, and alterations can be made as needed.
For most epithelial malignancies, radiation is commonly delivered in 1.8 to 2 Gy per fraction for 5 weeks to a total dose of 6,000 to 6,500 cGy. Hyperfractionation protocols vary, but 100 to 150 cGy often are delivered twice daily. Therapy can be accelerated to produce a total dose of 5,000 cGy in 3 weeks. Lymphomas in the head and neck usually are treated to a total dose of 3,500 to 5,000 cGy delivered at 180 to 200 cGy per day.
In external-beam therapy, the two principal field arrangements are parallel opposed fields (bilateral) and wedged-pair fields. The wedged-pair field allows a therapeutic dose to unilateral disease while sparing a high dose to the opposite side (Figure 8-28) . When a large tumor or midline lesion is present, a parallel opposed-field set-up or three-field set-up may be needed, which produces relatively uniform exposure for midline disease. Fields are often modified by placing wedges in the beam to accommodate the variation in tissue contour in the head and neck. A more complex set-up may be needed in some situations and may include three-field techniques, boost fields, and sequential-field set-ups to maximize therapeutic effects and reduce complications (Figure 8-29 ). Specific portions of fields such as the orbit, spinal cord, and portions of the alveolus may be blocked with lead (Figure 8-30 ).
BRACHYTHERAPY
Interstitial and intracavitary implants are used to treat primary cancers in the head and neck. Brachytherapy may the primary treatment modality for localized tumors in the anterior twothirds of the oral cavity, for boosted doses of radiation to a specific site, or for treatment following recurrence. The isotopes used include cesium, iridium, and gold. Directly implanted sources may be used to deliver radiation, or an afterloading technique may be used in which the radiation source is placed by using previously inserted guide tubes.
The frequency of tissue necrosis is related to the treated volume and to the proximity of the implant to bone. Tissue deflectors can be made to deflect the tongue so that an implant designed to treat a cancer of the tongue does not expose adjacent alveolar bone. These devices can be fabricated by using a double layer of flexible mouth guard material or by using heatcured acrylic (Figure 8-31 ). Lead foil can be added to the surface of the deflector if needed. Similarly, devices can be made to keep radiation from superficial treatment of the lip from affecting the alveolar bone (Figure 8-32 ). Lead cutouts can be made and placed on the skin to isolate the lesion; these may be used in combination with an intraoral device that can shield the intraoral tissues (Figure 8-33) .
Future developments in radiotherapy include investigations of radiation sources, radiation fractionation, radiosensitizers, radioprotectors, and combined therapy. 91, 128 Advances in radiotherapy that are currently being studied include the use of heavy charged particles (ie, neutrons), which may provide a more focused distribution of cellular damage and which are less sensitive to hypoxia than are conventional radiation sources. Methods of protecting tissues from late radiation effects (such as those that compromise the vasculature) are under study. Hyperfractionation (ie, the use of more than one fraction of radiation each day of therapy) may result in improved tumor control with a reduction in late complications; however, increased severity of oral mucositis is reported. 124, 129 Thus, efforts to prevent or palliate mucositis will reduce one of the treatment-limiting complications associated with hyperfractionation of radiation therapy. The development of in vitro clonagenic assays to determine tumor cell kinetics and susceptibility to therapy may lead to improvements in the selection of treatment.
Chemotherapy
Chemotherapy has been considered for treatment of individuals with advanced tumors or recurrent disease in whom surgery or radiation is unlikely to result in cure. Chemotherapy is used as induction therapy prior to local therapies, as simultaneous chemoradiotherapy, and as adjuvant chemotherapy after local treatment. 91, 130, 131 Combined chemotherapy and radiotherapy protocols are being investigated; regression of tumor has been seen, but no improvement in 5-year survival has been seen consistently. 128 The objective of adding chemotherapy is to promote initial tumor reduction and to provide early treatment of micrometastases. The potential toxic effects of chemotherapy include mucositis, nausea, vomiting, and bone marrow suppression. The principal agents that have been studied alone or in combination are methotrexate, bleomycin, taxol and its derivatives, cisplatin and platinum derivatives, and 5-fluorouracil. Chemotherapy for head and neck cancer may result in a temporary reduction in tumor size, but this has not translated into increased survival, control of the primary tumor, or a decreased incidence of metastasis. 2, 91, 128, 132, 133 The initial tumor response to chemotherapy prior to radiotherapy may predict tumor responsiveness to radiation. Research will continue and may include investigations into increasing the number of drugs used in combination; increasing the number of courses of chemotherapy provided; using modulators of chemotherapeutics, such as 5-fluorouracil and leucovorin; and modifying administration, such as by intermittent and continuous infusion.
Combined Radiation and Surgery
Advantages of radiotherapy is its ability to eradicate well-oxygenated tumor cells at the periphery of a tumor and to manage subclinical regional disease. Surgery more readily manages tumor masses with relatively radiation-resistant hypoxic cells and tumor that involves bone. Thus, combined therapy can result in improved survival in cases of advanced tumors and tumors that show aggressive biologic behavior. 123 Radiation can be used preoperatively, postoperatively, or with a planned split-course approach. There is no consensus on the best approach to combined therapy with preoperative or postoperative radiation. The advantages of preoperative radiation are the destruction of peripheral tumor cells, the potential control of subclinical disease, and the possibility of converting inoperable lesions into operable lesions. The disadvantages include difficulty in defining the exact tumor extent, delayed surgery, and delayed postsurgical healing. Surgery prior to radiotherapy can be used to remove the bulk of the tumor containing hypoxic cells. Postoperative radiotherapy can be used to treat cells that remain at the margin of resection and to control subclinical disease. Postoperative radiotherapy is chosen in specific cases, such as extensive carcinoma (in which a delay in healing due to preoperative radiotherapy could be critical), tumor that extends to the margin of the specimen, and extracapsular extension of tumor. Local control of the primary disease appears to be similar with preoperative or postoperative radiotherapy, but in some series, the incidence of metastases was lower in the postoperative group. 134, 135 Wellcontrolled clinical trials are needed to guide the choice of preoperative versus postoperative radiotherapy.
▼ OTHER HEAD AND NECK CANCERS
Malignant Tumors of the Salivary Glands
Tumors of the salivary glands, the majority of which involve the parotid glands, represent less than 5% of all head and neck tumors. Approximately two-thirds of these tumors are benign mixed tumors (pleomorphic adenomas). When tumors involve the submandibular or sublingual glands, there is a high probability that they will be malignant. In order of decreasing frequency, the malignant salivary gland tumors are mucoepidermoid carcinoma, adenoid cystic carcinoma, adenocarcinoma, squamous cell carcinoma, malignant pleomorphic adenoma, undifferentiated carcinoma, lymphoma, melanoma, and a mixed group of sarcomas. Most salivary gland tumors spread by local infiltration, by perineural or hematogenous spread, and (less commonly) through lymphatics. Rarely, metastases from other malignancies may involve the parotid glands. The cause of salivary gland tumors remains obscure, but ionizing radiation has been identified as a risk factor.
Malignant salivary gland tumors most commonly present as a mass that may be ulcerated. Neurologic involvement may lead to discomfort; with parotid gland tumors, involvement of the facial nerve may cause facial paralysis. Most small malignant lesions are indistinguishable from benign lesions. The majority of minor salivary gland tumors are malignant. The most common site is the posterior hard palate, but other sites in the oral cavity or upper respiratory tract may be involved. The presentation is usually a painless mass. The staging of salivary gland tumors is shown in Table 8-3. Necrotizing sialometaplasia is a self-limiting non-neoplastic inflammatory condition of unknown etiology that affects the palatal salivary glands. The painful lesion occurs in sites of mucus-secreting glands and produces an ulceration with rolled borders. Clinical and histologic differentiation may be difficult, but accurate diagnosis is critical because necrotizing sialometaplasia will resolve spontaneously, usually within 1 to 2 months.
Biopsy of masses in the major glands may be accomplished by FNA, and diagnosis may be made without open biopsy. However, surgical biopsy may be necessary if FNA is not diag-nostic. In masses involving minor glands, biopsy can be performed with routine techniques.
TREATMENT OF SALIVARY GLAND TUMORS
Surgery is the principle treatment of the primary tumor. Radiotherapy at a high dose is effective in malignant salivary gland tumors. 128 Postoperative radiation can contribute to cure and to improved local control and is indicated for patients with residual disease following surgery, extensive perineural involvement, lymph node involvement, high-grade malignant disease, tumors with more than one local recurrence after surgery, inoperable tumors, or malignant lymphoma and for those who refuse surgery. Doses and fractionation similar to those used in the treatment of squamous cell carcinoma are usually employed.
PROGNOSIS
The prognosis of salivary gland tumors is related to tumor type, tumor size, lymph node involvement, and extension of disease. 136 Small tumors, acinic cell tumor, low-grade mucoepidermoid carcinoma, and mixed tumors have a high probability of cure. Tumors with a poor prognosis include large tumors, adenocarcinoma, adenoid cystic carcinoma, high-grade mucoepidermoid carcinoma, poorly differentiated carcinoma, and squamous cell carcinoma. Histologic findings that correlate with lymph node involvement include deep (> 8 mm) and diffuse invasion of stromal tissue and invasion of lymphatics. 123 Adenoid cystic carcinoma has a high incidence of progression, and 10-and 15-year survivals must be examined due to late progression (recurrence may be seen after 10-15 years, therefore 10-15 year survivals should be assessed).
Malignant Lesions of the Jaw
Osteogenic sarcoma is the most common malignancy of bone. 2, 137 Its treatment requires surgery, possibly in combination with radiotherapy. Primary squamous cell carcinoma of the jaw is rare and may arise from epithelial rests or from the epithelium of odontogenic lesions.
Tumor metastatic to the jaw most often involves the posterior mandible. Metastases are rare, representing approximately 1% of all oral malignant tumors. 138 Common tumors that metastasize to the jaw are adenocarcinomas (of the breast, prostate, and gastrointestinal tract) and renal carcinoma. Other reported sites of primary tumors that metastasize include the thyroid, testes, bladder, ovary, and uterine cervix. Symptoms associated with metastases to the jaw may include pain, paresthesia, anesthesia, mobility of teeth, and swelling. Destruction of bone may be visualized with imaging (see Figure 8-21 ). Lesions in periapical regions can be mistaken for dental disease. Gingival masses can occur as signs of metastatic tumor; however, metastases to soft tissue are extremely rare, representing less than 0.1% of oral tumors. 138 Diagnosis requires biopsy. Multiple myeloma may cause radiolucent lesions in multiple bones, including the jaw. Multiple myeloma may cause periapical lesions and (because pain may be associated with the disease) must be distinguished from dental disease.
These conditions require definitive diagnosis before it is assumed that the lesions represent other than a dental pathosis. The practitioner must arrive at a definitive diagnosis before embarking on routine dental treatment.
Nasopharyngeal Carcinoma
Nasopharyngeal cancer has implications in dental practice because patients may present with complaints that may mimic temporomandibular disorders and because radiation therapy includes all major saliva glands, leading to hyposalivation and oral complications post treatment. Symptoms associated with nasopharyngeal carcinoma include pain, limited jaw opening, earache, and other ear complaints. The most common symptoms are nasal stuffiness, nosebleed, and neck mass.
Risk factors for nasopharyngeal carcinoma include EpsteinBarr virus infection, smoking, childhood consumption of salted fish and other preserved foods that are common in a Cantonese diet, and origin from southern China. 13, 113, [139] [140] [141] Long-term survival is approximately 50% because most patients are identified after the tumor has spread regionally and after lymph nodes are involved. 141, 142 FNA can provide tissue diagnosis, and the sensitivity can be enhanced by DNA amplification (polymerase chain reaction) of the Epstein-Barr virus genome, which is commonly associated with nasopharyngeal carcinoma but which is rare in other head and neck cancers. 143 Treatment requires radiation therapy and is increasingly combined with chemotherapy. A three-field set-up for radiotherapy is shown in Figure 8-29 . Surgery may play a role in involved neck nodes but not in the treatment of the primary tumor. Chemotherapy and immunotherapy in combination with radiation therapy have been reported. 141 Radiation therapy will result in radiation exposure of all of the salivary glands and in severe xerostomia.
Basal Cell Carcinoma
Basal cell carcinoma is a locally destructive cancer that may occur in the head and neck. Sun exposure is considered the principal etiologic factor. Basal cell carcinoma presents as persistent keratotic lesions (indurated papules) that may develop rolled borders and ulcerate. If advanced, they may lead to locoregional tissue necrosis and ulceration. Treatment may involve local excision or topical chemotherapy. While basal cell carcinoma rarely metastasizes, recurrence or second primary lesions are common. Dental workers have the opportunity to identify basal cell lesions on the head and neck if routine extraoral examination is conducted with care. 144 
Malignant Melanoma
Melanoma may present as an area of altered pigmentation involving the skin. Oral malignant melanoma is extremely rare 145 (2% of all melanomas). Among 65 patients with head and neck melanoma, two-thirds of the patients were in their sixth decade, and only 10% of cases involved the oral mucosa. 145 However, among Japanese people, oral lesions account for 14% of all cases of melanoma. 72 The oral lesions may present as tissue masses or ulceration that may be pig-mented, but nonpigmented lesions are often reported. Most intraoral cases occur in the maxillary mucosa, presenting as a mass or flat lesions that may ulcerate and that may be associated with bleeding. Melanoma is an aggressive malignant disease; metastasis through lymphatic and hematogenous routes is common, and the prognosis is poor. Aggressive therapy of the primary tumor and careful investigation for metastases are required.
Intraoral and Head and Neck Sarcoma
Intraoral sarcoma is a very rare disease with a poor prognosis. It may constitute approximately 1% of all head and neck cancers and only 0.14% of intraoral malignancies. 146 The lesions are most often identified as a mass, and the most common malignancy is rhabdomyosarcoma. Chondrosarcoma and osteosarcoma may involve the jaw, the commonest presentation being as a mass. 147 Treatment is wide surgical excision although combined chemoradiotherapy to improve the prognosis is being examined.
Head and Neck Malignant Disease in AIDS
HIV infection that leads to immunosuppression increases the risk of the development of neoplastic disease. 148 Advances in the management of HIV infection have lead to a reduction in the prevalence of manifestations of immunosuppression, but it is usually anticipated that HIV disease will ultimately progress and that oral findings will be identified. Kaposi's sarcoma (KS) is the most common neoplastic disease of acquired immunodeficiency syndrome (AIDS). Lymphoma is the most rapidly increasing malignant disease of AIDS. Non-Hodgkin's lymphoma, most commonly of B-cell origin, may present with central nervous system involvement but also may present with head, neck, or oral lesions. The lymphomas are aggressive and carry a poor prognosis. Oropharyngeal squamous cell carcinoma has been reported in patients with HIV disease; however, prevalence rates have not been determined.
KS is a multicentric neoplastic proliferation of endothelial cells. KS may occur in up to 55% of homosexual males with AIDS and may be the first sign of progression to AIDS or may occur during the course of the disease. KS is less common in AIDS patients whose risk factor is not sexual transmission, suggesting that KS is associated with a sexually transmitted agent, which has now been identified as human herpesvirus type 8 (HHV-8). As increasing numbers of intravenous drug abusers are affected, the frequency of KS has decreased. KS can involve any oral site but most frequently involves the attached mucosa of the palate, gingiva, and dorsum of the tongue. Lesions begin as blue purple or red purple flat discolorations that can progress to tissue masses that may ulcerate ( Figures  8-34 to 8-36 ). The lesions do not blanch with pressure. Nondiscolored KS also has been reported in the oral cavity. Initial lesions are asymptomatic but can cause discomfort and interfere with speech, denture use, and eating when lesions progress. The differential diagnosis includes ecchymosis, vascular lesions, and salivary gland tumors. Definitive diagnosis requires biopsy. Because KS is a multicentric neoplastic disease, multiple sites of involvement can occur, including skin, lymph nodes, gastrointestinal tract, and other organ systems.
Intralesional chemotherapy for treatment of oral KS has shown effective palliation. 145, [148] [149] [150] Intralesional treatment with vinblastine and interferon has been reported. The lesions can be treated with the injection of vinblastine (0.2 mg/mL) under local anesthesia. The effect of treatment may continue for several weeks and may result in palliation for approximately 4 months (see Figure 8-36 ). Repeat injection can be completed with similar efficacy. KS is radiosensitive, and radiation can be palliative for regional disease. Fractionated radiotherapy (for a total dose of 25 to 30 Gy over 1 to 2 weeks) may be provided for oral KS. Severe mucositis can follow radiotherapy for oral KS although this may be less severe with fractionated treatment. If KS progresses at multiple sites, systemic chemotherapy may be needed. New approaches to management that are being investigated include the use of cytokines that reduce angiogenesis and the use of antiviral agents for HHV-8 infection. 
▼ PRETREATMENT ORAL AND DENTAL ASSESSMENT
Detailed oral and dental assessment is necessary prior to cancer treatment. The oral assessment is needed to identify conditions that should be treated prior to cancer therapy, to (1) reduce the risk or severity of complications, (2) reduce the risk of infection involving the dentition and mucosa, and (3) minimize and manage the complications of hyposalivation.
The assessment also will aid the institution of a program for preventing caries. The acquisition of baseline data will allow assessment of the progress of the patient's oral condition during and following cancer therapy. The essential aspects of a pretreatment oral examination have been reviewed. 151 Pretreatment interventions are directed at the maintenance of mucosal and bony integrity, dental and periodontal health, salivary gland function and the prevention of potential complications of therapy. 152 The patient's history should review past dental care, current oral or dental symptoms, and the presence and condition of prostheses. The assessment must be comprehensive and must include head and neck examination (with attention to the presence of lymphadenopathy), intraoral mucosal examination, and periodontal and dental examination. The periodontal examination must include full periodontal probing. Periodontal attachment loss is greater in radiated fields, and this future attachment loss should be considered in preradiotherapy treatment planning. 153 Definitive dental diagnosis and management must be provided prior to radiation therapy because periodontal disease may require periodontal surgery or extractions, which are fraught with risk if the teeth involved were within the high-dose fraction. Radiographic examination should allow detailed evaluation of the teeth and periapical regions and should include imaging of any bone pathosis. Saliva production should be measured prior to therapy, to document any change in flow rate, which may predict a risk of oral complications. Study models should be acquired for the provision of gel carriers, for construction of surgical prostheses if indicated, and for permanent records. Cultures for patients with suspected infections of the mucosa (eg, Candida) are indicated throughout the course of treatment. Culture of cariogenic bacteria in xerostomic patients is important for the diagnosis of cariogenic risk and indicates the need for therapy (see "Caries," later in this chapter). A shift to cariogenic flora occurs due to hyposalivation and is not seen during radiation therapy in patients who are provided with fluoride and in those maintaining plaque control. 154 Plaque control and gingivitis at first examination provide evidence of past oral care habits, and unless it is believed that a true change in habits can be achieved, past practices should be expected to predict future care.
Prior to radiation therapy, teeth to be maintained should be scaled and root planed. Sites of potential mechanical irritation should be eliminated. The prevention of osteoradionecrosis requires the extraction of nonrestorable or questionable teeth, root tips, and periodontally involved teeth in the planned radiation field (see "Tissue Necrosis," later in this chapter). If time permits, asymptomatic periapical radiolucent lesions can be managed; however, endodontics can be performed following radiation if expert management is accomplished. Detailed review of oral hygiene, oral care during radiation therapy, and oral care following radiotherapy is an important part of long-term care.
▼ COMPLICATIONS OF CANCER TREATMENT
Acute reactions occur during the course of radiotherapy because of direct tissue toxicity and possibly secondary bacterial irritation resulting in ulcerative mucositis; these reactions resolve over several weeks following the completion of therapy. Chronic complications or late radiation reactions occur due to change in the vascular supply, fibrosis in connective tissue and muscle, and change in the cellularity of tissues. These complications develop slowly over months to years following treatment. The effect on the mucosa is one of epithelial atrophy, altered vascular supply, and fibrosis in connective tissue, resulting in an atrophic and friable mucosa. The connective tissue and musculature may demonstrate increased fibrosis. Fibrosis in muscle and joint tissue may result in limited function. In salivary glands, loss of acinar cells, alteration in duct epithelium, fibrosis, and fatty degeneration occur. In bone, hypovascularity and hypocellularity lead to the risk of osteoradionecrosis. Surgical treatment of the malignant disease results in acute pain and may result in chronic complications due to structural change, fibrosis, and neurologic changes. Hyperfractionation of radiation therapy may reduce the late complications but may increase the severity of the acute reactions. The antiprostaglandin effects and the effects of acetylsalicyclic acid (ASA) and nonsteroidal analgesics on platelet adhesion may reduce the vascular complications following radiation therapy. 155, 156 Low-dose ASA has been shown to increase stromal tolerance by 20% 156 and has the potential to reduce the severity of late radiation complications.
Mucositis
Ulcerative oral mucositis is a painful and debilitating condition that is a dose-and rate-limiting toxicity of cancer therapy. The potential sequelae of mucositis consist of severe pain, increased risk for local and systemic infection, compromised oral and pharyngeal function, and oral bleeding that affect quality of life, may lead to hospitalization or increase the duration of hospitalization, and may increase the cost of care. Mucositis is the most common cause of pain during the treatment of cancer. Pain due to oropharyngeal mucositis frequently requires the use of opioid analgesics, which is associated with increased costs and side effects. The increasing use of more aggressive therapy to improve cancer cure rates has increased the frequency and severity of oral complications. In neutropenic patients, the risk of systemic infection due to oral opportunistic and acquired flora is increased with mucosal ulceration. Increased risk of mucositis has been associated with poor oral hygeine, tobacco use, hyposalivation at baseline, and older age. [157] [158] [159] [160] [161] [162] Hyperfractionation, combined chemoradiotherapy, and the use of radiosensitizers cause increased severity of oral mucositis. The plasma level of glutamyl-cysteinyl-glycine (GSH) has been shown to predict the severity of acute radiation mucositis, 163 suggesting that GSH has a radioprotective role due to protection against either membrane lipid oxidation or DNA damage.
The literature does not provide definitive evidence for direct management of mucositis, but research is continuing. Most studies of oral mucositis involve small numbers of patients, many studies are preliminary rather than randomized placebo-controlled trials, and many suffer from the use of outcome measures that lack sensitivity and that are not validated. The wide variation in the quality of studies of mucositis makes the assessment of outcomes difficult and requires that reviewers carefully assess the methods employed in the study.
ASSESSMENT
Radiation-associated mucositis is virtually a universal complication in patients with head and neck cancer. The reported incidence and severity of mucositis depends on the methods used for oral assessment, as demonstrated in a study in which a chart review and an interview were conducted and in which mucositis was respectively identified in 30% and 69% of the same patients. 164 Clinical examination of tissue change and assessments of symptoms are the principal means of assessing mucositis. A recent study assessed and validated the use of the Oral Mucositis Assessment Scale (OMAS) and showed that the OMAS was easily used and demonstrated intrarater and interobserver reproducibility and temporal changes with treatment. 165 Other markers of mucositis may become available. Current investigations include cell morphology and viability of exfoliated buccal cells; the viability of cells was determined by the trypan blue dye exclusion test, and a shift from mature to immature cells was seen as mucositis developed. 166 Oral symptoms, function scales and validated measures of tissue damage currently represent the best means of assessing the outcome of treatment interventions.
PATHOGENESIS
Cytotoxic chemotherapy and radiation therapy have direct effects on mucosal epithelial cells, resulting in thinning of the epithelium and ultimately to loss of the barrier (see Table 8 -1). Connective tissue and vascular elements are also affected. Mucositis may include an initial inflammatory/vascular and epithelial phase that is followed by an ulcerative/bacteriologic phase and ultimately a healing phase. 167 In the initial phase, changes in cell surface molecules, 168 and epidermal growth factor (EGF) may increase the risk of mucositis, and cytokines that reduce epithelial cell proliferation may decrease the severity of tissue damage. 169 Interaction with cytokines produced in the connective tissue may affect tissue damage. The oral microflora appear to play a role in the development of ulceration and pseudomembrane, as suggested in studies of gram-negative bacterial flora in patients with radiation-induced mucositis. 167, 170 Shifts in the oral microflora include the development of a flora that is high in Streptococcus mutans, lactobacilli, Candida, and gram-negative bacilli, which may result in oral infections and may aggravate mucositis (Figure 8-37) . Resolution of mucositis is dependent on epithelial cell regeneration and angiogenesis and may also be dependent on white blood cell function and the production of growth factors. Pain associated with mucositis is dependent on the degree of tissue damage, the sensitization of pain receptors, and the elaboration of inflammatory and pain mediators. Oral defenses compromised due to irradiation include decreased mucosal cell turnover, increased permeability and loss of the mucosal barrier, changes in saliva secretion, reduced levels of antimicrobial factors in saliva, loss of protective mucins, and diluting effects. Impairment of the mobility of oral structures may lead to reduced clearing of local irritants and food products.
The first signs of mucositis may be a white appearance to the mucosa, caused by hyperkeratinization and intraepithelial edema, or a red appearance due to hyperemia and epithelial thinning (Figure 8-38 ). Pseudomembrane formation represents ulceration with a fibrinous exudate with oral debris and microbial components (Figures 8-39 and 8-40 ). Radiation has more marked effects on rapidly proliferating epithelium, and mucositis therefore involves the nonkeratinized mucosa first. Late changes in the mucosa reflect endarteritis and vascular changes associated with hypovascularity and with hyalinization of collagen 171 (Figure 8-41 ). With common fractions of 180 to 220 cGy per day, mucositis with erythema is noted in 1 to 2 weeks and increases throughout the course of therapy (often to a maximum in 4 weeks) with persistence until healing occurs 2 or more weeks after the completion of therapy. 172 Metallic dental restorations and appliances may produce secondary radiation when in the path of the radiation beam; this may increase the effect of irradiation on adjacent tissue, resulting in increased mucositis and risk of late effects. Thus, removable dental appliances should be removed during radiation; however, metal restorations are not removed, and their significance in complications is not well documented. The increasing use of dental implants will require consideration in future treatment planning for patients with head and neck cancer.
HYPOSALIVATION
Bilateral exposure of the major salivary glands to radiation therapy will predictably result in xerostomia. In patients who receive radiotherapy for treatment of Hodgkin's disease (ie, mantle fields), saliva production is affected when the upper limit of the field is at the chin to the mastoid; below this level, minimal long-term effects are seen. 173 Individuals who receive radiation doses greater than a total dose of 3,000 cGy are at risk if all major glands are in the field. Irreversible effects occur at a total dose of 6,000 Gy for 5 weeks. Radiation results in acinar cell atrophy and necrosis, changes in the vascular connective tissue, and altered neurologic function. During radiation, the serous acini are affected earlier than the mucinous acini, resulting in a thick viscous secretion that can be upsetting to the patient. Saliva production rapidly decreases and can be reduced by 50% after 1 week of standard fractionated radiation. Depending on the amount of salivary tissue included in the field, xerostomia may resolve within 6 months, but in many cases, the loss of function is permanent. A review of patients at 3 years post radiation therapy that included the major glands in the field showed a 95% reduction in saliva volume. 174 Xerostomia in such patients may be lifelong, and prevention of oral complications may therefore need to be continued indefinitely.
Changes in the composition of saliva also occur. Decreases in secretory immunoglobulin A, buffering capacity, and acidity are seen. [175] [176] [177] These changes affect the microbial flora and the remineralizing potential of teeth. The goals in the management of xerostomia are to stimulate the remaining salivary gland function and (if such stimulation is not achieved) to palliate xerostomia, prevent tooth demineralization and caries, and manage microbial shifts.
RADIATION THERAPY-RELATED MUCOSITIS AND FUNGAL AND VIRAL COLONIZATION
Radiotherapy-related mucositis is the most frequent complication in patients receiving irradiation for head and neck cancers. Chronic oral sensitivity frequently continues after treatment, due to mucosal atrophy (33%) and neurologic syndromes attributed to de-afferentation (16%). 178, 179 Oral colonization by Candida spp and candidiasis is common during and following radiotherapy and is related to hyposalivation and to denture and tobacco use. 154, 180 The role of fungal colonization and infection in radiation mucositis is not clearly understood. In a group of patients receiving head and neck irradiation, patients who were on fluconazole developed 1 mycotic infection and had 14 nonscheduled breaks in radiation therapy, compared to 19 infections and 30 breaks in radiation therapy for those who were not provided with fungal prophylaxis. 181 However, an association between candidiasis or oral colonization and mucositis during irradiation has not been confirmed by other studies. 182 The potential role of the reactivation of HSV during head and neck radiation therapy is unclear, and reactivation of HSV infection does not appear to commonly complicate radiation mucositis. 183 
SYSTEMIC APPROACHES TO MANAGEMENT
Pain Management. Management of severe oropharyngeal mucositis often requires the use of systemic opioids (Table  8-4) . Systemic analgesics should be prescribed by following the World Health Organization (WHO) analgesic "ladder," which suggests the use of non-opioid analgesics, alone or in combination with opioids and adjunctive medications, for increasing pain. 184 Analgesics should be provided on a timecontingent basis, with provision for breakthrough pain. While there may be patient and professional concerns regarding the use of opioids for cancer pain, difficulty in stopping the analgesic does not occur if pain resolves, and addiction is not a concern in oncology patients. Rather, the concern is with the underuse of analgesics and with underdosing that leads to poor pain control. 184 There has been limited study of the use of adjunctive approaches to pain management in patients with oral mucositis. Relaxation, imagery, biofeedback, hypnosis, and transcutaneous electrical nerve stimulation have the potential to provide adjunctive approaches for the management of cancer pain. 184 The use of hypnosis has been shown to be a valuable adjunct, 185, 186 and relaxation and imagery reduce the pain experience. 187 Systemic prednisone provided to patients with head and neck cancer in a double-blind protocol resulted in a trend to reduced severity and duration of mucositis, and fewer treatment interruptions occurred. 188 However, the use of steroids may result in increased risk of infection. Systemic β-carotene administered during a combined course of chemotherapy and radiotherapy for patients with advanced head and neck squamous carcinoma has been reported to reduce the severity of mucositis. 189 Radioprotectors. Amifostine (Ethyol) is a sulfhydryl compound that acts by scavenging free radicals generated in tissues exposed to radiation and that promotes repair of damaged DNA. Amifostine has been shown to protect a variety of tissues, including mucosa, cardiac tissue, renal tissue, bone marrow, and neuro-and ototoxicity when administered prior to irradiation and chemotherapy. There is reduced uptake of amifostine into tumor, and tumor protection is not seen. Trials are under way to assess the use of amifostine in patients with cancer (including head and neck cancer) who are being treated with chemoradiotherapy. Side effects include nausea, vomiting, and reversible hypotension. Administration requires prehydration, and intravenous administration is necessary prior to each fraction of irradiation. In initial studies of patients receiving chemoradiotherapy for head and neck cancer, those who received amifostine (compared to those who received no intervention) had reduced mucositis [190] [191] [192] and xerostomia. [190] [191] [192] [193] Amifostine has been approved in the United States for reduction of renal toxicity secondary to cisplatin administration and for reduction of xerostomia in patients who are treated with radiotherapy. This agent has potential for reducing the effects of the acute and chronic toxicity of cancer therapy, including mucositis. However, further study including cost-benefit analysis is needed.
Biologic Response Modifiers.
Extensive studies have been conducted on biologic response modifiers. These are molecules that affect cellular function, including growth and tissue repair. Early findings on the effect of granulocyte colonystimulating factor (G-CSF) upon reducing oral mucositis have been described although this has not been confirmed in other studies. 194 Granulocyte-macrophage colony-stimulating factor (GM-CSF) has shown benefits in a number of initial clinical trials in patients treated with chemoradiotherapy. [195] [196] [197] [198] Keratinocyte growth factor (KGF), a member of the fibroblast growth factor family, binds to KGF receptor, accelerating the healing of wounds. 199 Systemic KGF modifies the proliferation and differentiation of epithelial cells and may protect the cells from damage. Animal studies have shown the potential of KGF to reduce mucositis caused by radiation and chemotherapy. [199] [200] [201] Double-blind controlled trials are in progress.
TOPICAL APPROACHES TO MANAGEMENT
The effect of oral hygiene and the elimination of local irritants may have an impact on the development of mucositis. Maintaining good oral hygiene has been shown to reduce the severity of oral mucositis and does not increase the risk of septicemia in neutropenic patients. 93 Mucositis is not reduced with the use of chlorhexidine rinses during radiation therapy. 170, 202, 203 This may be due to the inactivation of chlorhexidine by saliva, the lack of an etiologic role for gram-positive bacteria (which are suppressed by chlorhexidine) in mucositis, and a limited effect of chlorhexidine on gram-negative organisms that may be important in the development of ulcerative mucositis. Other studies, using an oral lozenge containing polymyxin, tobramycin, and amphotericin B, have shown an effect on Candida colonization and gram-negative bacilli, and a reduction in mucositis was reported. 170, 204 Palliation of mucositis may be achieved by the use of bland oral rinses and topical anesthetic and coating agents; however, controlled studies are lacking (see Table 8 -4) . Saline, bicarbonate, dilute hydrogen peroxide, and water also have been suggested for hydrating and diluting by rinsing. Lip applications with water-based lubricants (eg, lubricating jelly, such as K-Y Jelly [Johnson & Johnson] ) or preparations that contain lanolin have been suggested rather than the use of oil-based products because the chronic use of oil-based products (eg, Vaseline) results in the atrophy of epithelium and the risk of infection under occlusion of the application. A study comparing saline and hydrogen peroxide rinses in radiation therapy found no significant differences among patients with mucositis although oral sensitivity was greater in those using peroxide. 205 Coating agents used as oral rinses, such as milk of magnesia, liquid Amphogel, and Kaopectate (Pharmacia Corp., Peapack, N.J.) are often recommended but have not been subjected to double-blind studies. 184 Viscous lidocaine is frequently recommended although there are no studies that assess its benefit or its potential for toxicity in cancer patients. Lidocaine may cause local symptoms that include burning and that eliminate taste and affect the gag reflex. Potent topical anesthetic agents should be used with caution due to their potential for decreasing the gag reflex, causing central nervous system depression or excitation and causing cardiovascular effects that may follow excessive absorption. Local applications of topical anesthetic creams or gels may be useful for local painful mucosal ulcerations. A combination of agents that may include a coating agent and an analgesic or anesthetic agent also have been suggested, but no randomized controlled studies of mixtures of agents have been reported.
Benzydamine hydrochloride (Tantum, Riker-3M, Canada; Diflam, UK) is a nonsteroidal agent that possesses analgesic anti-inflammatory properties and is mildly anesthetic. Benzydamine may stabilize cell membranes, inhibit the degranulation of leukocytes, affect cytokine production, and alter the synthesis of prostaglandins. Signs and symptoms of oral mucositis are reduced when benzydamine is used prophylactically throughout the course of radiation therapy. 170, 172, 203, [206] [207] [208] [209] However, another study, comparing the use of chlorhexidine and benzydamine, did not show less severe mucositis in patients using benzydamine rinse. 210 Benzydamine is currently available in Europe and Canada and is under review by the US Food and Drug Administration (FDA).
Sucralfate is a cytoprotective agent that is available for the management of gastrointestinal ulceration. The agent may form a barrier on the surface of ulcerated mucosa in acidic conditions and may stimulate the release of prostaglandins. Sucralfate suspension has been studied in patients with mucositis, and less severe mucositis has been reported in some studies 211 but not in the majority of studies. [212] [213] [214] However, reduced oral pain was reported for sucralfate users compared to placebo users. 212, 213 Another potential benefit is a reduction in potentially pathogenic oral organisms in patients with mucositis. 212, 215, 216 Because of its coating and protective effects, sucralfate may be useful in the palliation of established mucositis. A comparison of sucralfate and a diphenhydramine-plus-kaolin-pectin suspension did not show a greater efficacy for either suspension, but reduced mucositis was seen in both groups when compared to historic controls. 216 Misoprostol is a synthetic prostaglandin E analogue that is used for the prevention of gastric ulcers for patients on nonsteroidal anti-inflammatory medication, due to its antisecretory and mucosal protective effects. Topical application of misoprostol in head and neck cancer patients treated with irradiation has been reported to be beneficial in one of two centers studied. 217 Further study is continuing.
Hydroxypropyl cellulose has been applied to isolated ulcers and may form a barrier on the surface, reducing symptoms. 218 Hydroxypropyl cellulose also has been combined with topical anesthetic agents (eg, benzocaine), with clinical reports of efficacy. Further research is needed to provide evidence of efficacy of its topical application in the management of oral complications of cancer patients.
Chlorhexidine has been assessed in radiotherapy patients, 203, 219 and the majority of studies do not demonstrate a prophylactic impact on mucositis. 220, 221 The effects of chlorhexidine on plaque levels, gingival inflammation, caries, and oral streptococcal colonization have not been the primary end points in these studies, but they may be valuable during cancer therapy. A prospective study of patients treated with chemoradiotherapy for head and neck cancer showed that mucositis was reduced in those who received oral applications of povidone iodine, compared to those who received sterile water rinses. 221 However, the impact of oral hygiene may be a confounding factor in these studies.
Studies of the use of a nonabsorbable antimicrobial lozenge that combines polymixin, tobramycin, and amphotericin B in conjunction with radiation therapy for head and neck cancer have shown the medication to reduce gram-negative bacterial colonization and to prevent oral ulcers. 195, 222 A double-blind placebo-controlled trial of 112 patients found that patients' self-reports of severe mucositis were lessened but that mucositis scores were not different. 222 Studies of topical antimicrobials for prevention of mucositis are continuing.
Oral capsaicin in a taffylike candy vehicle produced temporary partial pain reduction in 11 patients with oral mucositis pain. 223 The findings suggest that some of the pain of mucositis is mediated by substance P.
Radiation shields to protect normal tissue from radiation exposure are often suggested during radiation therapy. They were shown to be effective, with patients experiencing less weight loss, fewer hospitalizations for nutritional support, and a trend toward fewer treatment interruptions when compared with control patients. 242 Interest in the use of cytokines in the prevention and treatment of mucositis is increasing. An animal model of mucositis has been used to assess the potential of growth factors to affect oral mucositis. [225] [226] [227] [228] [229] [230] In this model, epidermal growth factor (EGF) increased the severity of mucosal damage when given concurrently with chemotherapy. 230 Transforming growth factor beta-3 (TGF-β3), which reduces the proliferation of epithelial cells, reduced the incidence, severity, and duration of mucositis; however, this finding has not been confirmed in human trials to date. 227, 228 The use of interleukin-11 (IL-11) resulted in a statistically significant reduction in mucositis. 225, 226, 229 A rat model of inflammatory bowel disease also showed a reduction in gross and microscopic damage to the colon in animals treated with IL-11. 229 Due to hyposalivation, the quantity of EGF in saliva decreased in people receiving head and neck irradiation, and its concentration in saliva decreased as mucositis increased. 168 EGF may represent a marker for mucosal damage and has the potential to promote the resolution of radiation-induced mucositis. A double-blind trial of EGF mouthwash used in patients treated with chemotherapy showed no differences in the healing of established ulcers, but a delay in onset and reduced severity were seen in recurrent ulceration, suggesting that topical EGF may protect the mucosa from toxicity. 231 Several preliminary studies have assessed the effect of GM-CSF on oral mucositis, 195, 232, 233 and a less severe or reduced duration of mucositis was seen in several trials.
Low-energy helium-neon laser has been reported to reduce the severity of oral mucositis in patients receiving head and neck radiation therapy. 234 The mechanism of action is unknown but has been suggested to be due to cytokine release following laser exposure.
CURRENT MANAGEMENT
Current management of mucositis in radiotherapy patients (see Table 8 -4) includes an emphasis on good oral hygiene, the use of frequent oral rinses for wetting the surfaces and diluting oral contents, avoidance of irritating foods and oral care products, avoidance of tobacco products, and the use of benzydamine (in countries where it is available). The management of oropharyngeal pain in cancer patients frequently requires systemic analgesics, adjunctive medications, physical therapy, and psychological therapy, in addition to local measures, oral care, and topical treatments.
Biologic response modifiers offer the potential to prevent oral mucositis and to speed the healing of damaged mucosa. Antimicrobial approaches have met with conflicting results; chlorhexidine and systemic antimicrobials have little effect in preventing mucositis in radiation patients, but there is increasing evidence of the effectiveness of topical antimicrobials that affect gram-negative oral flora. Thiol derivatives, including amifostine, have been associated with radioprotection and have potential for clinical application. Other approaches that require further study surface wetting, inhibition of overgrowth of pathogenic microorganisms, maintenance of the hardness of dental structure, pleasant taste, long duration of effect, extended shelf life, and low cost. The majority of products currently available are based on carboxymethylcellulose. Animal mucins have been incorporated into some European products. Most commercial products are more viscous than saliva and do not simulate the non-newtonian viscoelastic properties of saliva. They also do not contain the complex enzyme systems and antibodies of natural saliva. Many of the commercial products being marketed have not been subjected to controlled clinical study.
Candidiasis
In radiated patients, the most common clinical infection of the oropharynx is candidiasis. During radiation therapy, the number of patients colonized by Candida, quantitative counts, and clinical infection all increase 151, 154, 159, 202, [238] [239] [240] (see . These changes persist in patients, with continuing hyposalivation. The role of Candida spp in oral mucositis associated with radiation therapy is not known. Candidiasis may enhance the discomfort of mucositis and may be associated with discomfort and changes in taste after treatment.
Patients who receive radiation therapy should be managed with topical antifungals because oral candidiasis produces oral discomfort but does not lead to systemic infection unless the patient is immunocompromised. 241 When prescribing topical antifungal drugs, the presence of sucrose in the product must be known because frequent use of sucrose-sweetened products may promote caries, particularly in patients with dry mouth.
Caries
Caries associated with hyposalivation typically affect the gingival third and the incisal cusp tips of the teeth (Figure 8-42 ). The etiology is related to a lack of production of saliva, resulting in loss of remineralizing potential, loss of buffering capacity, increased acidity, and a change in the bacterial flora. Treatment of each component of the caries process must be addressed.
Oral hygiene must be scrupulously maintained. Hyposalivation should be managed, and thorough trials of sialagogues should be conducted. The tooth structure may be hardened by the use of fluorides, and remineralization may be enhanced by the use of fluorides and remineralizing products. 170, [242] [243] [244] [245] [246] The effects of topical products may be enhanced by increased contact time on the teeth which can be achieved by applying them with occlusive vacuform splints or gel carriers, which should extend over the gingival margins of the teeth. Custom vinyl trays are most useful for the application of fluoride to prevent and control caries in high-risk patients. 151, 170, 174, 244, 245 A comparison of neutral sodium fluoride gel in carriers with a twice-daily fluoride rinse protocol suggested a similar efficacy of the rinse protocol, but this was not a controlled comparative study. 246 Further studies are needed to define the simplest effective protocol. However, until controlled studies are available, treatment should remain fluoride application in gel carriers; for those who do not comply with carrier application, high-potency brush-on fluoride dentrifice may be suggested as it is simpler and include low-energy lasers and (possibly) anti-inflammatory medications.
Xerostomia STIMULATION OF SALIVARY FUNCTION
The use of sialagogues offers the advantage of stimulating saliva secretion, which may include all normal components which provide the protective functions of saliva. Measurement of saliva flow rates to determine the amount of residual function should be conducted before prescribing a sialagogue. If no saliva is collected under resting or stimulated conditions, it is unlikely that a systemic agent will be effective. The use of sugarless gum or candies also may assist the stimulation of residual gland function.
Pilocarpine is the best studied sialagogue. 2, [235] [236] [237] [238] [239] Pilocarpine is a parasympathomimetic agent and has its major effects at the muscarinic cholinergic receptor of salivary gland acinar cells. In doses of up to 15 mg/d, increased secretion of saliva occurs, and few cardiovascular side effects have been noted. Anetholetrithione (Paladin Laboratories Inc, Montreal, Canada) has been reported to be beneficial in the management of dry mouth. 237 The mechanism of action may be to increase the number of cell surface receptors on salivary acinar cells. Because pilocarpine stimulates the receptors and because anetholetrithione may act by stimulating the formation of receptor sites, synergistic effects may result with the combined use of these drugs. 237 Bethanechol and bromhexine have received limited study. 2, 236 Bethanechol (75 to 200 mg/d in divided doses), which stimulates the parasympathetic nervous system, has been reported to have potential benefits without causing gastrointestinal upset. Bromhexine has been studied in patients with dry mouth due to Sjögren's syndrome, without evidence of an increase in saliva volume; however, no studies of bromhexine have been conducted in cancer patients.
Stimulation of the salivary glands during radiation therapy has been suggested as a possible means of reducing damage to the glands. Patients who begin radiation therapy with higher initial flow rates retain more residual flow. 173 Preliminary study of the prophylactic use of pilocarpine (5 mg qid) in patients receiving radiation therapy suggests that parotid gland function may be better preserved; however, this effect was not demonstrated in submandibular and sublingual gland saliva following treatment. 175 Amifostine, which is administered intravenously prior to radiation exposure, has been licensed by the FDA for prevention of salivary gland dysfunction and may reduce the severity of oral mucositis; however, additional study is needed to determine its impact on mucositis and its cost versus benefit.
PALLIATION
Mouth-wetting agents or saliva substitutes may be used when it is not possible to stimulate salivary function. 236 Frequent sipping of water and a moist diet are mandatory. The desired characteristics of saliva substitutes are excellent lubrication, as it may reduce demineralization and caries. Continuing reinforcement of topical fluoride use is needed and will enhance patient compliance.
A shift to a cariogenic flora has been well documented in patients following head and neck radiation therapy. A high risk of caries that is associated with Streptococcus mutans and Lactobacillus spp has been demonstrated in cancer patients. 247, 248 Assessment of quantities of cariogenic organisms should be carried out before considering whether antimicrobials are needed. A high risk of caries is reported if more than 10 5 Streptococcus mutans and more than 10 4 Lactobacillus colony-forming units per milliliter of saliva are present. Topical fluorides and chlorhexidine rinses may reduce levels of Streptococcus mutans. 247, 248 A 2% chlorhexidine gel applied in mouth guards demonstrated an enhanced ability to control cariogenic flora in cancer patients with xerostomia. 249 
Tissue Necrosis
Soft-tissue necrosis may involve any oral site, including the cheeks and tongue. Involvement of tissue overlying bone that has received high-dose radiation may predispose to necrosis of soft tissue and bone (Figure 8-43 ). Postradiation osteonecrosis (PRON) may be chronic or progressive. A classification of PRON for identifying stages of the condition for research and clinical purposes and for guiding therapy has been described 250, 251 (Table 8-4) . Radiation therapy causes endarteritis that affects vascularity, resulting in hypovascular, hypocellular, and hypoxic tissue that is unable to repair or remodel itself effectively when a challenge occurs (Figure 8-44 ). The challenge may take the form of trauma (such as from surgical procedures), active periodontal disease or denture trauma, and idiopathic or spontaneous necrosis for which no known cause is identified. While PRON may be secondarily infected, the infection is not etiologic. Symptoms and signs may include discomfort or tenderness at the site, bad taste, paresthesia and anesthesia, extraoral and oroantral fistulae, secondary infection, and pathologic fracture. The primary risk factor for the development of PRON is radiation therapy, in which dose, fraction, and numbers of fractions result in the biologic effect (eg, a high risk when TDF > 109). The volume of bone included in the field of irradiation increases the risk. The presence of teeth in a high-dose radiation field represents a risk factor for PRON, probably in relation to dental or periodontal disease or irritation. The risk of necrosis is lifelong and may occur many years after irradiation. The risk of developing PRON has been estimated in the last 20 years as between 2.6 and 15%. 250, 215 The mandible is most commonly involved although cases can occur in the maxilla.
The prevention of PRON begins with the preradiation dental examination and with radiotherapy treatment planning. Teeth in the high-dose fraction with questionable prognosis (particularly when due to periodontal disease and when excellent compliance with regular oral care is unlikely) should be extracted prior to radiotherapy. If extractions are planned, it is desirable to allow as much healing time as possible; 7 to 14 days and up to 21 days have been suggested as healing times prior to radiotherapy. 251, 252 The time required may depend on the nature of the extraction, and expert atraumatic extraction will require less healing time.
When PRON develops, management should include having the patient avoid mucosal irritants, discontinue the use of dental appliances if they contact the area of the lesion, maintain nutritional status, and stop smoking, and eliminate alcohol consumption. Topical antibiotic (ie, tetracycline) or antiseptic (chlorhexidine) rinses may reduce the potential local irritation from the microbial flora. For chronic persisting PRON (stage II), this therapy and regular follow-up may be the best approach to treatment. Hyperbaric oxygen (HBO) therapy increases the oxygenation of tissue, increases angiogenesis, and promotes osteoblast and fibroblast function. In cases associated with symptoms of pain and progression (stage III), HBO is an important part of therapy. Appropriate analgesia should be provided. HBO therapy and surgical guidelines have been established. 252, 253 HBO therapy is usually prescribed as 20 to 30 dives at 100% oxygen and 2 to 2.5 atmospheres of pressure. Sequestra may be managed with limited resection or may require mandibulectomy. If surgery is required, postsurgical HBO therapy of 10 dives is recommended. The mandible can be reconstructed to provide continuity for esthetics and function. Prophylactic HBO therapy may be considered (1) when surgery is required after radiation therapy, (2) when the patient is felt to be at extreme risk due to high-dose radiation to the bone with a high biologic effect (TDF > 109), and (3) when extensive surgery is required. However, if expert atraumatic extraction is performed, HBO therapy may be considered only if delayed healing occurs. In a select population of patients referred for HBO therapy and surgery, prophylactic HBO therapy was suggested. 252 In a general cancer clinic, however, extractions were managed with expert surgery, and approximately 5% of extractions were associated with delayed healing; it was recommended that in most cases, HBO therapy should be reserved for those in whom osteonecrosis developed. 251 A number of studies have reported the effect of HBO on necrosis, and several have concluded that HBO therapy is an important part of the comprehensive management of necrosis following radiation therapy. [254] [255] [256] A long-term follow-up of patients after their first episode of necrosis showed that in 20 of the 26 patients who were available for follow-up, 10% experienced a recurrence of necrosis following HBO therapy. 255 In 60% of these patients, the condition remained stable, and no recurrence of signs and symptoms of necrosis occurred; in 10%, a further improvement occurred over time while 20% of the patients continued to demonstrate persisting (stage 2) necrosis. This study supports the potential value of HBO therapy in managing initial episodes of necrosis and FIGURE 8-43 A, Chronic exposure of bone in the mandibular region, following radiation therapy. There was local discomfort, and the area was tender to palpation. B, Another case of exposure of mandibular bone due to postradiation osteonecrosis. Involvement extends to the periodontal support of the bicuspid and to the molar region of the lingual plate. The adjacent tissue of the floor of the mouth shows the telangiectatic appearance of late radiation changes. C, Panoramic radiograph of a case of postradiation osteonecrosis, demonstrating bone destruction approaching the inferior border of the mandible, leading to an increased risk of pathologic fracture. dysphagia. Consideration must be given to taste, texture, moisture, and caloric and nutrient content.
Mandibular Dysfunction
Musculoskeletal syndromes may arise due to fibrosis of muscles, which may follow radiation and surgery. Limited opening has been related to radiation exposure of the upper head of the lateral pterygoid muscle. Mandibular discontinuity following surgery and the emotional stress associated with malignant disease and its treatment may influence musculoskeletal syndromes and pain. Mandibular stretching exercises and prosthetic aids may reduce the severity of fibrosis and limited mandibular movement when conducted before severe limitation has developed, but few benefits are seen after such limitation has developed. The management of temporomandibular disorders in this population may present additional difficulties due to major discontinuity of the mandible, with severe limitation of function and emotional reaction. There is no research that documents the best choices of therapy for these patients. Therapy may include occlusal stabilization appliances, physiotherapy, exercises, trigger point injections and analgesics, muscle relaxants, tricyclic medications, and other chronic pain management strategies. 260 Management of pain is discussed later in this chapter.
Dentofacial Abnormalities
When children receive radiotherapy to the facial skeleton, future growth and development may be affected. 261 Agenesis of teeth, agenesis of roots, abnormal root forms, or abnormal calcification may occur (Figure 8-46 ). Despite these dental abnormalities, teeth will erupt even without root formation and may be retained for years. Growth of the facial skeleton in the radiated field may be affected, which can result in micrognathia, retrognathia, altered growth of the maxilla, and asymmetric growth (Figure 8-47 ). Altered growth and development may occur if treatment affects the pituitary gland. Trismus occur in patients secondary to fibrosis of muscles.
in potentially preventing the recurrence of second episodes. In addition, the findings indicate that stage 2 chronic necrosis may remain stable and without progression over extended periods following initial treatment with HBO therapy. A number of studies have reported the effect of HBO therapy on necrosis, and several have concluded that HBO therapy is an important part of the comprehensive management of necrosis following radiation therapy. 150, [254] [255] [256] 
Speech and Mastication
Abnormal speech may follow surgery or radiation because of hyposalivation and fibrosis that affects tongue mobility, mandibular movement, and soft-palate function (Figure 8-45 ).
Maxillectomy that produces a palatal defect must be managed with prostheses to allow function in speech, mastication, and deglutition. Speech therapy and prostheses are the principal means of managing these complications.
Nutrition
Radiation therapy produces changes in the patient's perceptions of taste and smell. 257 Taste may be affected directly due to an effect on the taste buds, or indirectly, due to hyposalivation and secondary infections. A total fractionated dose of > 3,000 Gy reduces the acuity of all tastes (ie, sweet, sour, bitter, and salty). 258 Taste often will recover slowly over several months, but permanent alteration may result. 2 Zinc supplementation (zinc sulfate, 220 mg twice daily) may be useful for some patients who experience taste disturbances. 2, 259 Nutritional counseling in which the focus is on the maintenance of caloric and nutrient intake may be required during therapy. Following treatment and when mucositis has resolved, nutritional counseling must consider the long-term complications that may occur. These include hyposalivation, an altered ability to chew, difficulty in forming the food bolus, and 
FIGURE 8-45
Results of a partial glossectomy that has led to functional impairment of speech and manipulation of food and to difficulty in retaining the mandibular denture.
The dental abnormalities pose significant management challenges due to these effects on dental development and skeletal growth.
Pain
Head, neck, and oral pain may be caused by the tumor or by cancer therapy or may be unrelated to cancer 260 (Table 8-6) . Pain, whether related to the tumor, recurrence or progression of tumor, treatment of tumor, or unrelated to the cancer, often is interpreted as being due to the disease and is influenced by an emotional response caused by fear of cancer. The important emotional components of the reaction to pain must be considered in the patient's complaint and in management. Pain at diagnosis of head and neck cancer is common, is reported in up to 85% of those seeking treatment, and is usually described as low-grade discomfort. 260 Acute pain following radiotherapy and surgery is universal.
Health care providers have been criticized for the needless suffering of patients caused by the providers' lack of understanding of the use of analgesics and adjuvant medications, lack of attention to the emotional and social aspects of pain, and failure to use adjunctive physical and psychological treatment. The management of cancer pain requires attention to the potential multiple causes of pain (see Table 8 -6) .
Dental and periodontal disease that causes pain may be controlled with analgesics and antibiotics; however, definitive dental management is needed. Management of mucositis is discussed earlier in this chapter. Bacterial, fungal, and viral infections are managed with specific antimicrobial agents. In mucosal infection, topical antifungals and antiseptics may be effective, but if resolution does not occur, systemic medications may be needed.
Neurologic pain states, including neuropathic pain and neuralgia-like pain, may require the use of antidepressants and anticonvulsants, respectively. Management of osteonecrosis is discussed in this chapter. In all cases of persisting pain, chronic pain management approaches including counseling, relaxation therapy, imagery, biofeedback, hypnosis, and transcutaneous nerve stimulation may be needed. Pain associated with musculoskeletal syndromes is described in the section entitled "Mandibular Dysfunction."
Analgesics should be provided according to the level of pain, the drug's pharmacologic action, and the duration of action of the drug. They should be combined with adjuvant medications according to the multiple causes of pain and the secondary effects of pain (Table 8-7) . Analgesics, when required, should be provided on a regularly scheduled or time-contingent basis, not on an as-needed basis. Improved pain control requiring lower total doses of analgesics can be achieved with medication provided on a time-contingent basis. In general, non-narcotic analgesics should be provided to all patients even if potent opioids are required because this Radiograph showing the effects of radiation on the development of the dentition. Agenesis, shortened root forms, lack of root development, and premature closure of apical foramina are seen in teeth that were in the primary radiation field and that were in the process of development during radiation therapy.
FIGURE 8-47
Radiograph demonstrating the effect of unilateral radiation that was required during dentofacial development. Asymmetric development of height and width of the ramus and body of the mandible and dentition resulted. may allow a lower dose of narcotic medication. Adjuvant medications such as tricyclics anti-depressants may enhance the analgesic effects of other agents, possesses analgesic potential themselves, and promotes sleep, which is often disrupted by pain. Adjuvant medications directed at the etiology of the pain should be used whenever possible. For example, for neuralgia-like pain, anticonvulsant medications should be included. Possible side-effects, such as constipation due to opioids, should be anticipated and treated. Reassessments of the efficacy of pain control, with an awareness of toxicity and side effects, should be conducted on a regular basis. Medications should not be used alone but should be part of a pain control strategy that also includes physical therapy, counseling, relaxation therapy, biofeedback, hypnosis, and transcutaneous nerve stimulation.
▼ CONCLUSION
Oral and dental care is important in all phases of the diagnosis and treatment of the patient with head and neck cancer. Early recognition and diagnosis are important for improving survival and for limiting the complications of therapy. Prevention of the oral complications that arise during or after therapy and management of the complications when they occur require the involvement of a knowledgeable practitioner. Dental providers are a part of the health care team and must be involved in the care of the head and neck cancer patient. Continuing research is needed in the epidemiology, pathogenesis, etiology, prevention, diagnosis, and management of head and neck cancer. 
